Clot retrieval device for removing occlusive clot from a blood vessel

Information

  • Patent Grant
  • 11147572
  • Patent Number
    11,147,572
  • Date Filed
    Friday, September 1, 2017
    7 years ago
  • Date Issued
    Tuesday, October 19, 2021
    2 years ago
Abstract
A clot retrieval device for removing occlusive clot from a blood vessel. The device comprises an inner elongate body having a collapsed delivery configuration and an expanded deployed configuration. An outer elongate body is at least partially overlying the inner elongate body. The outer elongate body is expandable to a radial extent which is greater than the radial extent of the inner body in the deployed configuration to define a clot reception space. The outer elongate body has a plurality of clot receiving openings and a plurality of clot engaging regions. The clot engaging regions are adapted, on engagement with clot, to urge clot towards the clot receiving openings and into the reception space between the outer elongate body and the inner elongate body, wherein the radial force profile of the device varies along the length of the device.
Description
FIELD OF THE INVENTION

This invention relates to devices and methods of removing acute blockages from blood vessels. The invention especially relates to removing acute obstructions from blood vessels. Acute obstructions may include clot, misplaced devices, migrated devices, large emboli and the like. Thromboembolism occurs when part or all of a thrombus breaks away from the blood vessel wall. This clot (now called an embolus) is then carried in the direction of blood flow. An ischemic stroke may result if the clot lodges in the cerebral vasculature. A pulmonary embolism may result if the clot originates in the venous system or in the right side of the heart and lodges in a pulmonary artery or branch thereof. Clots may also develop and block vessels locally without being released in the form of an embolus—this mechanism is common in the formation of coronary blockages. The invention is particularly suited to removing clot from cerebral arteries in patients suffering acute ischemic stroke (AIS), from pulmonary arteries in patients suffering from pulmonary embolism (PE), from coronary native or graft vessels in patients suffering from myocardial infarction (MI), and from other peripheral arterial and venous vessels in which clot is causing an occlusion.


BACKGROUND

There are significant challenges associated with designing clot removal devices that can deliver high levels of performance:


There are a number of access challenges that make it difficult to deliver devices. In cases where access involves navigating the aortic arch (such as coronary or cerebral blockages) the configuration of the arch in some patients makes it difficult to position a guide catheter. These difficult arch configurations are classified as either type 2 or type 3 aortic arches with type 3 arches presenting the most difficulty. The tortuosity challenge is even more severe in the arteries approaching the brain. For example it is not unusual at the distal end of the internal carotid artery that the device will have to navigate a vessel segment with a 180° bend, a 90° bend and a 360° bend in quick succession over a few centimetres of vessel. In the case of pulmonary embolisms, access may be gained through the venous system and then through the right atrium and ventricle of the heart. The right ventricular outflow tract and pulmonary arteries are delicate vessels that can easily be damaged by inflexible or high profile devices. For these reasons it is desirable that the clot retrieval device be compatible with as low profile and flexible access and support catheters as possible.


The vasculature in the area in which the clot may be lodged is often fragile and delicate. For example neurovascular vessels are more fragile than similarly sized vessels in other parts of the body and are in a soft tissue bed. Excessive tensile forces applied on these vessels could result in perforations and hemorrhage. Pulmonary vessels are larger than those of the cerebral vasculature, but are also delicate in nature, particularly those more distal vessels.


The clot may comprise any of a range of morphologies and consistencies. Long strands of softer clot material may tend to lodge at bifurcations or trifurcations, resulting in multiple vessels being simultaneously occluded over significant lengths. More mature and organized clot material is likely to be less compressible than softer fresher clot, and under the action of blood pressure it may distend the compliant vessel in which it is lodged. Furthermore the inventors have discovered that the properties of the clot may be significantly changed by the action of the devices interacting with it. In particular compression of blood clot causes dehydration of the clot and results in a dramatic increase in both clot stiffness and coefficient of friction.


The clots may not only range in shape and consistency, but also may vary greatly in length, even in any one given area of the anatomy. For example clots occluding the middle cerebral artery of an ischemic stroke patient may range from just a few millimeters to several centimeters in length.


Stent-like clot retrievers are being increasingly used to remove clot from cerebral vessels of acute stroke patients. These are self expanding devices, similar in appearance to a stent attached to the end of a long shaft, and are advanced through a microcatheter and deployed across clot obstructions in order to trap and retrieve them. They rely on a pinning mechanism to grab the clot by trapping the clot between the self-expanding stent-like body and the vessel wall. This approach has a number of disadvantages:


A stent-like clot retriever relies on its outward radial force (RF) to retain its grip on the clot. If the RF is too low the stent-like clot retriever will lose its grip on the clot, but if the RF is too high the stent-like clot retriever may damage the vessel wall and may require too much force to withdraw. Therefore stent-like clot retrievers that have sufficient radial force to deal with all clot types may cause vessel trauma and serious patient injury, and stent-like clot retrievers that have appropriate radial force to remain atraumatic may not be able to effectively handle all clot types.


The stent-like clot retriever pinning mechanism tends to compress the trapped clot. This compressive force will tend to dehydrate the clot, which in turn tends to increase its coefficient of friction, making it more difficult to remove from the vessel.


Conventional Stent-like clot retriever designs do not retain their expanded shape very well when placed in tension in bends, due to the manner in which their strut elements are connected to one another. This can result in a loss of grip on a clot as the stent-like clot retriever is withdrawn proximally around a bend in a tortuous vessel, with the potential escape of the captured clot. This occurs because the struts of the stent-like clot retriever are placed in tension when it is retracted. This tension is due to friction between the device and the blood vessel, and is increased if an additional load is applied load such as that provided by a clot. In a bend the struts on the outside of the bend are placed in higher tension than those on the inside. In order to attain the lowest possible energy state the outside surface of the stent moves towards the inside surface of the bend, which reduces the tension in the struts, but also reduces the expanded diameter of the stent-like clot retriever.


Another disadvantage with this approach is that it relies on pinning the clot between the stent-like clot retriever and the vessel wall and thus may not restrain the clot effectively when passing a branch vessel or when passing into a vessel that is larger than the fully expanded diameter of the stent-like clot retriever.


Pinning the clot between the stent-like clot retriever and the vessel wall in order to remove it from the vessel also results in high shear forces against the side of the clot as it is removed, potentially releasing fragments of the clot. If these fragments are not retained by the device they may be released leading to further blockages in the distal vasculature.


A particular difficulty encountered when attempting to remove long clots is that conventional devices may be shorter than the clot itself. A device that is shorter than the clot is unlikely to be able to restore flow through the occluded area upon deployment, and thus the pressure gradient across the clot remains a significant impediment to its removal. Simply making such a device longer would likely render it difficult to track through tortuous anatomies and could be traumatic to the vasculature, taking more force to withdraw and potentially getting stuck and requiring surgery to remove.


For many reasons including some or all of the above limitations it is often necessary for a physician to make multiple passes with a clot retrieval device in order to fully remove an obstructive clot. However each time a clot retrieval device is withdrawn the access to the target site is lost. Thus it is necessary to re-advance a guidewire and microcatheter to access and re-cross the clot, and then remove the guidewire and advance the clot retrieval device through the microcatheter. Navigating the guidewire and microcatheter to the clot can take a considerable amount of time especially if the vessels are tortuous. This additional time and device manipulation all adds to the risks to which the patient is exposed.


The challenges described above need to be overcome for any device to provide a high level of success in removing clot, restoring flow and facilitating good patient outcomes. Existing devices do not adequately address these challenges.


STATEMENTS OF THE INVENTION

According to the invention there is provided a clot retrieval device for removing occlusive clot from a blood vessel, the device comprising:

    • an inner elongate body having a collapsed delivery configuration and an expanded deployed configuration;
    • an outer elongate body at least partially overlying the inner elongate body;
    • the outer elongate body being expandable to a radial extent which is greater than the radial extent of the inner body in the deployed configuration to define a clot reception space;
    • wherein the radial force profile of the device varies along the length of the device.


In one embodiment the outer elongate body comprises a plurality of clot receiving openings and a plurality of clot engaging regions. The clot engaging may be adapted, on engagement with clot, to urge clot towards the clot receiving openings and into the reception space between the outer elongate body and the inner elongate body,


In one case the radial force at a distal end of the device is lower than that at a middle section of the device.


The radial force at a distal end of the device may be lower than that of a middle section and a proximal section of the device.


In one embodiment the device comprises a plurality of segments and the radial force of one segment is different than the radial force of at least one other segment. The difference in radial force between the segments may be less than 20%, or less than 10%.


In one case the radial force increases along the length of the device from proximal to distal.


In another case the radial force of a mid segment is greater than the radial force of the distal segment.


In yet another case the radial force of a mid segment is greater than that of the proximal segment and the distal segment.


In one embodiment the outer body comprises a plurality of segments.


In one case a segment comprises a proximal ring of closed cells having a first radial force to which are connected at least one floating cell or leaflet having a second radial force which is less than the first radial force. The second radial force may be from 20% to 80%, or from 40% to 60% lower than the first radial force.


In one embodiment the clot inlet openings of the segments of the outer body differ along the length of the device.


In one case clot inlet openings in a proximal region of the device are smaller than clot inlet openings in a distal region of the device.


In another case the clot inlet openings in a middle section of the device are smaller than those in a more proximal and/or a more distal region of the device.


In a further case the clot inlet openings in a middle section of the device are larger than those in a more proximal and/or a more distal region of the device.


In one embodiment there is a gradient of the size of the clot inlet openings along the length of the device.


In one case the gradient increases from proximal to distal.


In another case the gradient decreases from proximal to distal.


In some embodiments the inner elongate body is tapered. The taper of the inner elongate body may be opposite to the gradient of the clot inlet openings in the outer body.


In another aspect of the invention the outer elongate member comprises a framework formed by struts and crowns and wherein proximal radiopaque markers are located at a distal end of struts which are proximally adjacent to proximal crowns.


According to the invention there is provided a clot retrieval device for removing occlusive clot from a blood vessel, the device comprising:

    • an inner elongate body having a collapsed delivery configuration and an expanded deployed configuration;
    • an outer elongate body at least partially overlying the inner elongate body;
    • the outer elongate body being expandable to a radial extent which is greater than the radial extent of the inner body in the deployed configuration to define a clot reception space;
    • wherein the outer elongate body comprises a distal end portion; and
    • wherein the inner elongate body comprises a main body portion and a distal portion which extends in the deployed configuration towards the outer elongate body to a greater extent than the main body portion,
    • the distal portion of the inner elongate member and the distal end portion of the outer elongate body together defining a three dimensional protective structure to substantially prevent distal egress of clot or clot fragments from the device.


In this aspect of the invention the embolization risk is reduced by providing a distal net or scaffolding zone across the vessel lumen towards the distal end of the device. This scaffolding in this case is appended to both the inner or outer member or to both members, and is three dimensional in that it has depth as well as surface area. Combining the scaffolding of both inner and outer members provides a more effective filter than utilizing one member alone. In some cases fibres or fine wires are utilised to provide added scaffolding with minimal impact on device profile or deliverability.


In one embodiment the distal portion of the inner elongate body comprises a plurality of struts which are configured in a volumetric pattern.


In one case the distal portion of the inner elongate body comprises a bulged or flared framework of struts.


In one embodiment the distal end portion of the outer elongate body comprises distal struts. In one case the distal struts of the distal end portion of the outer elongate member are configured in a generally conical shape.


In one embodiment at least some of the struts comprise an attachment point, such as an eyelet, for reception of a fibre. The protective structure may include a plurality of fibres providing a distal net.


In one embodiment the outer elongate body comprises a first monolithic structure.


In one embodiment the inner elongate body comprises a second monolithic structure.


In one case wherein the inner elongate body extends proximally of a proximal end of the outer elongate body.


In one embodiment the outer elongate body comprises a plurality of clot receiving openings and a plurality of clot engaging regions, and wherein the clot engaging regions are adapted, on engagement with clot, to urge clot towards the clot receiving openings and into the reception space between the outer elongate body and the inner elongate body.


The clot engaging regions of the outer elongate body comprises scaffolding openings, the clot receiving openings being substantially larger than the scaffolding openings.


In one embodiment the outer elongate body comprises at least two longitudinally spaced-apart segments. There may be at least one hinge is provided between the segments.


The disclosed designs overcome many of the disadvantages of existing mechanical thrombectomy solutions.


Various interchangeable terms are used herein to describe those portions of the invention that are configured to engage with the clot, being generally deployed within the clot and engaging with it. These terms include “clot engaging portion”, “expandable member”, “expandable body”, “clot engaging element”; while the terms “elongate basket”, “engaging basket” and “stent basket” may also be used to describe this portion of the device.


Designs are disclosed in which a clot engaging portion of the device is configured to be expanded within an occlusive clot in a blood vessel so that the expanding engager allows the clot to migrate into a reception space within the body of the engager as the engager expands. The engager is delivered through a catheter to the site of the occlusion and is positioned within the clot. The engager is expandable at the site of the occlusion and starts to compress the clot as it is expanded. The engager surface comprises inlet openings and the inlet openings allow the clot to ‘escape’ from compression by displacing a significant portion of the clot through the inlet openings in the wall of the engager. Because a significant portion of the clot is urged through the inlet openings in the engager this minimizes compression of the clot and hence minimizes the resultant increase in the clot coefficient of friction. This also reduces the radial force on the vessel in the region of the clot which means a lesser force is required to withdraw the captured clot, which in turn means less vessel trauma and less tension on the distal vascular bed. The device is configured such that the radial force of the device acts strongly at a small diameter to engage with and grip clot, but acts softly at a larger diameter to gently contact the vessel wall are also disclosed.


The radial force profile of the device may be further tailored along the device length. For example in one embodiment of the device of this invention the radial force of the distal end of the device is lower than that of the middle section of the device. In one embodiment the radial force of the distal end of the device is lower than that of the middle and proximal sections of the device. In one embodiment of the device of this invention the device comprises a plurality of segments, and the radial force of any segment may be the same or different from the adjacent segment. In one embodiment of such a device the radial force of all the segments is balanced such that the radial force of any given segment differs by less than 20%, and more preferably by less than 10%, from the radial force of any other segment. In one embodiment of such a device the radial force of any given segment differs by less than 20%, and more preferably by less than 10%, from the radial force of an adjacent segment. In one embodiment of such a device the radial force of all the segments is tailored such that the radial force generally decreases along the length of the device from proximal to distal. In one embodiment of such a device the radial force of all the segments is tailored such that the radial force generally increases along the length of the device from proximal to distal. In another embodiment the radial force of a mid segment is greater than that of the distal segment. In another embodiment the radial force of a mid segment is greater than that of the proximal and distal segments.


The radial force of the device of this invention can be further tailored within each individual segment of the outer expandable member. In particular, a segment of the outer expandable member may comprise a proximal ring of connected closed cells of a first radial force to which are connected one or more floating cells or leaflets of a second radial force. These floating cells or leaflets are distinguished by the fact that their distal apices are not connected to a more distal portion of the device—rather they are floating or disconnected. This allows these leaflets to act as trapdoors through which clot may fall into the inner reception space of the device. They may further act as trap features which are better able to remain open and apposed to the vessel wall as the device is retracted around bends and past branch vessels, helping to retain any trapped clot. In one embodiment the second radial force is lower than the first radial force. In one embodiment the second radial force is between 20% and 80% lower than the first radial force. In a preferred embodiment the second radial force is between 40% and 60% lower than the first radial force.


Designs with dual expandable members are disclosed whereby the device comprises a first inner expandable member and a second outer expandable member the inner member being arranged substantially within the lumen of the outer member. The properties of the inner and outer members may be tailored independently of each other. The inner member may have a very different radial force to the outer member. The inner member may have a very different level of porosity to the outer member. The inner member may have a fully expanded diameter that is very different to that of the outer member. The length of the inner member may be different to that of the outer member. The shape of the struts of the inner member may be different to the shape of the struts of the outer member. There may be a clearance between the inner member and the outer member in the expanded configuration. There may be a clearance between the inner member and the outer member in the collapsed configuration. One, or both or neither of the inner and outer members may have a seam which runs substantially longitudinally along at least a portion of the wall of the member. One, or both of the inner and outer members may comprise a laser cut member, a braided member, a knitted member, an extruded member, a pultruded member, One or both of the inner and outer members may be manufactured with a process involving a laser cutting step, a braiding step, a knitting step, an extrusion step, a pultrusion step, an electropolishing step, a heat treatment step. One or both of the inner and outer members may comprise a tapered section, a flared section, a closed end section or a closed mid section. One or both members may comprise a substantially tubular or cylindrical section.


One embodiment of an inner member of this invention comprises an interconnected strut framework forming a generally tubular section, where the struts of the framework define cells or openings, and said cells or openings define the porosity of the member. This tubular section may comprise different cell patterns and a variety of cell shapes. In one embodiment there are at least two cells around the circumference of any given section through the device. In a preferred embodiment there are at least three cells around the circumference of any given section through the device. Greater numbers of cells will provide a more dense and less porous structure, which will be more capable of maintaining a flow lumen through soft clot but at the cost of device flexibility and profile. The optimum number of cells depends therefore on the consistency of the material in which the device is to be deployed and on the diameter to which the member is designed to expand. Greater diameters may require greater numbers of cells to maintain an appropriate and effective level of porosity. A cell area of less than 4.0 mm2 is desired in order to achieve an adequate degree of clot scaffolding. However a cell area of less than 0.5 mm2 may cause unwanted blood coagulation or thrombosis, making the device difficult to clean for reuse and potentially generating harmful clot fragments. Therefore a cell area of between 1.0 mm2 and 3.0 mm2 is most preferred.


An inner expandable member expanded diameter of between 0.75 mm and 2.5 mm is likely to be most suitable for neurovascular applications of the invention. An inner expandable member expanded diameter of between 0.75 mm and 1.75 mm with a 3 or 4 cell structure is most preferred.


The diameter of the generally tubular inner member may vary along its length. In one embodiment the inner member diameter has a generally conical shape. In one embodiment the inner member diameter tapers from a smaller proximal diameter to a larger distal diameter. In one embodiment the inner member diameter tapers from a larger proximal diameter to a smaller distal diameter. In one embodiment the inner member diameter tapers from a diameter of approximately 0.75 mm-1.75 mm to a diameter of approximately 1.5 mm-4.0 mm.


These dual expandable member devices have a number of benefits. (1) The inner member can be configured to provide a strong opening force to create a lumen through the clot and restore flow immediately on deployment. This flow lumen reduces the pressure gradient across the clot, making it easier to remove the clot. (2) The diameter to which the inner member expands may be tailored so as to reduce the risk of a reperfusion injury. With this embodiment the inner member expands to a diameter that is significantly smaller than the diameter of the vessel immediately adjacent to and distal of the occlusion. This small diameter inner member creates a small flow lumen across the occlusion and restricts the initial blood flow to the affected portion of the brain. This restricted blood flow ensures that the pressure applied to blood vessels immediately after flow restoration is lower than normal and this reduces the risk of bleeding in the ischemic vascular bed. Full perfusion is subsequently restored by removing the device and the clot. (3) The inner member may be configured to expand to a lesser diameter than the outer basket and to a lesser diameter than any vessel in which it is to be deployed. This means that a strong radial force may be safely exerted on the clot to open up a flow lumen, but need not be exerted on the vessel. (4) The inner member can serve to scaffold the lumen created through the clot, preventing the liberation of emboli from the clot into the resultant fast flowing bloodstream. (5) The inner member may at least partially comprise a stent and can provide a strong grip on the clot for the critical initial step of disengaging the clot from the vessel, enabling the outer basket to be configured with a low radial force. (6) The outer member may be configured to have large inlet openings so as to urge clot across the wall of the outer. The inner member on the other hand may be configured to prevent distal migration or fragmentation or embolization of clot that traverses the wall of the outer member. By configuring the outer member so as to encourage clot to traverse the wall of the outer member the device can more effectively disengage clot from the wall of the vessel while the device is also effective at preventing loss of clot material with an inner member with a shape and substructure that provides scaffolding.


The inlet openings of the outer member may be further tailored to cater for the range of clot types and sizes that may be encountered clinically. Large inlet openings are desirable for accepting clot into the inner reception space of the device for secure clot capture, but may be disadvantageous when attempting to retain a secure grip on the clot as it is retracted proximally past bends and branches. In one embodiment the inlet openings may differ along the length of the device. In one embodiment the inlet openings in a proximal region of the device are larger than the inlet openings in a distal region of the device. In one embodiment the inlet openings in a proximal region of the device are smaller than the inlet openings in a distal region of the device. In one embodiment the inlet openings in a middle section of the device are smaller than those in a more proximal and/or distal region of the device. In one embodiment the inlet openings in a middle section of the device are larger than those in a more proximal and/or distal region of the device. In one embodiment a gradient of inlet openings is provided. In one such embodiment this gradient increases from proximal to distal so that a clot that fails to enter a smaller more proximal opening may be trapped by a larger more distal opening as the device is retracted. In one such embodiment this gradient decreases from proximal to distal so that any clot entering a larger more proximal opening will not be able to exit a smaller more distal opening as the device is retracted. Such an outer member may be combined with a tapered inner member to further assist in clot demobilisation and trapping—so that a clot entering through a large proximal opening of the outer member adjacent a small diameter portion of the inner member is prevented from migrating distally along the device by the increasing diameter of the more distal portion of the tapered inner member.


Various embodiments of the invention are described in more detail below. Within these descriptions various terms for each portion of the devices may be interchangeably used as discussed previously. Each of the described embodiments are followed by a list of further qualifications (preceded by the word “wherein”) to describe even more detailed versions of the preceding headline embodiment. It is intended that any of these qualifications may be combined with any of the headline embodiments, but to maintain clarity and conciseness not all of the possible permutations have been listed.


In one embodiment of the invention the treatment apparatus comprises a clot retrieval device comprising: an elongate member, and an expandable clot engaging element configured to extend across the clot in its expanded state, the expandable clot engaging element comprising a first monolithic structure and a second monolithic structure, the first monolithic structure encircling the second monolithic structure over at least a portion of its length, the second monolithic structure comprising a proximal section, an intermediate section and a distal section, the distal section comprising an expansion.


Some optional features of this embodiment include:

    • wherein the first monolithic structure is configured to substantially encapsulate the second monolithic structure;
    • wherein the first monolithic structure comprises a proximal section, an intermediate section and a distal section, the distal section comprising an enclosed distal end;
    • wherein the distal end of the clot engaging element comprises an enclosed distal end said enclosed distal end configured to capture clot fragments and/or to prevent distal migration of clot fragments;
    • wherein the expansion is configured to prevent clot fragment migration;
    • wherein the distal end of the first monolithic structure comprises an enclosed distal end said enclosed distal end defining a surface the surface configured as a clot fragment barrier surface;
    • wherein the clot fragment barrier surface comprises an interconnected network of struts;
    • wherein the distal section of the clot engaging element is configured to provide a three dimensional barrier to clot migration;
    • wherein the device further comprises a elongate connector element said elongate connector element comprising a proximal end and a distal end, the proximal end connected to the second monolithic structure and the distal end connected to the first monolithic structure;
    • wherein the elongate connector element comprises a spring element and said spring element is integral with the second monolithic structure;
    • wherein the first monolithic structure and the second monolithic structure are connected at their distal ends;
    • wherein the first monolithic structure and the second monolithic structure are not connected at their distal ends; and/or
    • wherein the proximal sections of said first and second monolithic structures are connected to a distal end of the elongate member.


In another embodiment of the invention the treatment apparatus comprises a clot retrieval device comprising: an elongate member, and an expandable clot engaging element configured to extend across the clot in its expanded state, the expandable clot engagement element comprising a proximal segment, a clot engaging segment and a distal segment, the proximal segment configured to extend proximal of the clot in use and the distal end configured to extend distal of the clot in use, the clot engaging segment configured to engage with the clot in its expanded state, the distal end comprising a fragment protection structure, the fragment protection structure comprising a plurality of struts configured in a volumetric pattern.


Some optional features of this embodiment include:

    • wherein the volumetric pattern comprises at least partially a conically shaped volumetric pattern;
    • wherein the volumetric pattern comprises at least partially a cylindrical volumetric pattern;
    • wherein the volumetric pattern comprises at least one plurality of interconnected struts;
    • wherein the volumetric pattern comprises at least two pluralities of interconnected struts;
    • wherein the volumetric pattern comprises a first plurality of struts arranged about a first axis and a second plurality of struts arranged about a second axis;
    • wherein the position of the first axis is moveable relative to the position of the second axis;
    • wherein the first axis and the second axis comprise centre lines and in use said centre lines may comprise straight and/or curved centre lines;
    • wherein the centrelines are deflectable relative to one another;
    • wherein the volumetric pattern comprises a terminal end;
    • wherein the terminal end comprises a terminal junction for at least some of said plurality of struts;
    • wherein the terminal end comprises a connection point at which said plurality of struts are terminated and/or connected;
    • wherein the volumetric pattern comprises a first plurality of struts, and a second plurality of struts;
    • wherein the second plurality of struts is at least partially encompassed by the first plurality of struts;
    • wherein the second plurality of struts encircles the first plurality of struts;
    • wherein the first plurality of struts is arranged about a first axis and the second plurality of struts is arranged about a second axis and said first and second axes are substantially parallel;
    • wherein the first plurality of struts is arranged about a first axis and the second plurality of struts is arranged about a second axis and said first and second axes are substantially parallel;
    • wherein the first plurality of struts comprises a conical shape; and or
    • wherein the second plurality of struts comprises a spherical shape, a flattened spherical shape, a cylindrical shape or a spindle torus shape.


In another embodiment of the invention the treatment apparatus comprises a clot retrieval device comprising: an elongate member, and an expandable clot engaging element comprising a first tubular structure and a second tubular structure, the first tubular structure at least partially encircling the second tubular structure, the first tubular structure comprising a proximal end, a distal end, a proximal termination and a distal termination, the second tubular structure comprising a proximal end, a distal end, a proximal termination and a distal termination, the proximal termination of the first and second tubular structures being connected to the elongate member and the distal terminations of the first and second tubular structures being connected to each other.


Some optional features of this embodiment include:

    • wherein the first tubular structure and the second tubular structure comprise monolithic structures of interconnected struts;
    • wherein the first tubular structure and the second tubular structure comprise longitudinally extending structures;
    • wherein both the first tubular structure and the second tubular structure comprise collapsed delivery configurations and expanded deployed configurations and the first tubular structure at least partially encircling the second tubular structure in both the expanded configurations and the collapsed configurations;
    • wherein one or both of the first tubular structure and the second tubular structure comprise a proximal collar for connecting one or both of the first tubular structure and the second tubular structure to a distal end of the elongate member;
    • wherein the at least one proximal collar comprises a partial collar; and/or
    • wherein the at least one proximal collar is cut from a hypotube and encircles at least a portion of a distal end of the elongate member.


In another embodiment of the invention the treatment apparatus comprises a clot retrieval device comprising: an elongate member, and an expandable clot engaging element comprising a first tubular structure and a second tubular structure, the first tubular structure at least partially encircling the second tubular structure, the first tubular structure and the second tubular structure connected to a distal end of the elongate member at a connection point, the first tubular structure comprising a first proximal connecting strut and a first connector element, the second tubular structure comprising a second proximal connecting strut and a second connector element, the first connector element encircling the second connector element at the connection point.


Some optional features of this embodiment include:

    • wherein the first connector comprises a collar;
    • wherein the second connector comprises a collar or partial collar; and/or
    • wherein the elongate member comprises a distal safety stop configured to prevent distal movement of the first connector and/or the second connector.


In another embodiment of the invention the treatment apparatus comprises a clot retrieval device comprising: an elongate member, and an expandable clot engaging element configured to extend across the clot in its expanded state, the expandable clot engagement element comprising a first luminal structure and a second luminal structure, the first luminal structure being larger in diameter than said second luminal structure, the distal end of said first luminal structure comprising a plurality of struts converging towards the axis of the first luminal structure, the distal end of said second luminal structure comprising a plurality of struts diverging away from the axis of said second luminal structure.


Some optional features of this embodiment include:

    • wherein the distal end of said first and second luminal structures are configured to form a three dimensional clot fragment migration barrier;
    • wherein the distal end of said second luminal structure further comprises an inflection region where a tangent to said plurality of struts is substantially parallel to the axis of said second luminal structure;
    • wherein the distal end of said second luminal structure further comprises a converging region where said plurality of struts converged on the axis of said second luminal structure;
    • wherein the distal end of said second luminal structure further comprises a second distal junction where said plurality of struts terminate;
    • wherein the distal end of said first luminal structure further comprises a first distal junction where said plurality of struts terminate;
    • wherein the first distal junction is distal of the second distal junction; and/or
    • wherein the first distal junction is connected to the second distal junction by a connector element.


In another embodiment of the invention the treatment apparatus comprises a clot retrieval device comprising: an elongate member, and a clot engaging element comprising a collapsed delivery state and an expanded clot engaging state, the clot engaging element configured to extend across the clot in its expanded state, the clot engaging element comprising a proximal section, an intermediate section and a distal section, the intermediate section comprising a luminal structure and the distal section comprising an expansion region.


Some optional features of this embodiment include:

    • wherein the diameter of the expansion region is larger than the diameter of the intermediate section in the expanded state;
    • wherein the clot engagement element comprising plurality of struts connected in a monolithic structure;
    • wherein the expansion region comprises a region of divergence and a region of convergence;
    • wherein the expansion region comprises an inflection point between the region of divergence and the region of convergence;
    • wherein the expansion region is integral with the intermediate section;
    • wherein the expansion region comprises a transition section the transition section comprising a plurality of struts connection the expansion region to the intermediate section;
    • wherein the expansion region comprises a tapering distal end;
    • wherein the device comprises an elongate member connected to the distal end of the expansion region; and/or
    • wherein in the expanded state the luminal structure is configured to define a flow lumen through the clot.


In another embodiment of the invention the treatment apparatus comprises a device for removing clot from a blood vessel comprising: an elongate member, and an expandable clot engaging element configured to extend across the clot in its expanded state, the expandable clot engagement element comprising a first luminal structure and a second luminal structure, the first luminal structure being larger in diameter than said second luminal structure and encircling at least a portion of the second luminal structure, the second luminal structure comprising a clot capture structure at its distal end, the clot capture structure comprising a flared section.


Some optional features of this embodiment include:

    • wherein the clot capture structure comprises a plurality of struts and at least one fibre configured into a filter;
    • wherein in the expanded state the diameter of at least a portion of the clot capture structure is similar to the diameter of the blood vessel;
    • wherein in the expanded state the diameter of at least a portion of the clot capture structure is larger than the diameter of the second luminal structure; and/or
    • wherein in the expanded state the diameter of at least a portion of the clot capture structure is similar to the diameter of the first luminal structure.


In another embodiment of the invention the treatment apparatus comprises a clot retrieval device comprising an elongate member, a first expandable member and a second expandable member; both expandable members having a proximal section, a body section, and a distal section, the body section of the first expandable member in the freely expanded state being larger in diameter than that of the second expandable member in the freely expanded state, and the proximal section of the first expandable member being distal of the proximal section of the second expandable member.


Some optional features of this embodiment include:

    • wherein the distal section of the first expandable member comprises a clot capture structure;
    • wherein the distal section of the second expandable member comprises a clot capture structure;
    • wherein the clot capture structure comprises a plurality of struts;
    • wherein the clot capture structure comprises a plurality of struts and at least one fibre configured into a filter;
    • wherein the proximal end of the first expandable member is connected to the distal section of the elongate shaft;
    • wherein the proximal end of the first expandable member is connected to the second expandable member;
    • wherein the proximal end of the second expandable member is connected to the distal section of the elongate shaft;
    • wherein the distal end of the first expandable member is not connected to the distal end of the second expandable member;
    • wherein the distal end of the first expandable member is connected to the distal end of the second expandable member;
    • wherein the body section of the second expandable member in the freely expanded state is less than 50% of the diameter of the body section of the first expandable member in the freely expanded state;
    • wherein the body section of the second expandable member in the freely expanded state is less than 40% of the diameter of the body section of the first expandable member in the freely expanded state;
    • wherein the body section of the second expandable member in the freely expanded state is less than 30% of the diameter of the body section of the first expandable member in the freely expanded state; and/or
    • wherein the body section of the second expandable member in the freely expanded state is less than 20% of the diameter of the body section of the first expandable member in the freely expanded state.


A method of using a clot retrieval device to retrieve a clot from a vessel, said clot retrieval device comprising an expandable body and an elongate shaft, said method comprising: delivering the device through a microcatheter to a target site, retracting the microcatheter to deploy the device at least partially within or beneath the clot, expanding a proximal section of the expandable member within a proximal section of the clot to a diameter smaller than that of the vessel, expanding a distal section of the expandable member distal of the clot to a diameter substantially equal to that of the vessel, withdrawing the device and clot proximally and removing both from the patient.


Some optional features of this embodiment include:

    • wherein the expandable body comprises an inner expandable member and an outer expandable member;
    • wherein the expanded diameter of the inner expandable member is smaller than that of the outer expandable member;
    • wherein at least a portion of the inner expandable member extends within at least a portion of the outer expandable member;
    • wherein at least a portion of the inner expandable member extends proximal of the outer expandable member;
    • wherein the distal section of the expandable body comprises a clot capture structure;
    • wherein the clot capture structure is connected to the inner expandable member;
    • wherein the clot capture structure is connected to the outer expandable member; and/or
    • wherein the elongate shaft extends outside of the patient in use.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be more clearly understood from the following description of some embodiments thereof, given by way of example only, with reference to the accompanying drawings, in which:



FIG. 1a shows a side view of a clot retrieval device of this invention;



FIG. 1b shows a side view of a clot retrieval device of this invention;



FIG. 1c shows a detail view of a portion of FIG. 1a;



FIG. 2a shows a view of a component of a clot retrieval device of this invention;



FIG. 2b shows a view of a component of a clot retrieval device of this invention;



FIG. 2c shows a view of a component of a clot retrieval device of this invention in its unexpanded state;



FIG. 2d shows a detail view of the proximal portion of FIG. 2c;



FIG. 3a shows a view of a component of a clot retrieval device of this invention;



FIG. 3b shows a view of a component of a clot retrieval device of this invention in its unexpanded state;



FIG. 3c shows a detail view of a portion of FIG. 2c;



FIGS. 4a-4f illustrate a method of use of a device of this invention;



FIG. 5 shows a side view of a clot retrieval device of this invention;



FIG. 6 shows a side view of a clot retrieval device of this invention; and



FIG. 7 shows a side view of a clot retrieval device of this invention.





DETAILED DESCRIPTION

Specific embodiments of the present invention are now described in detail with reference to the figures, wherein identical reference numbers indicate identical or functionality similar elements. The terms “distal” or “proximal” are used in the following description with respect to a position or direction relative to the treating physician. “Distal” or “distally” are a position distant from or in a direction away from the physician. “Proximal” or “proximally” or “proximate” are a position near or in a direction toward the physician.


Accessing cerebral, coronary and pulmonary vessels involves the use of a number of commercially available products and conventional procedural steps. Access products such as guidewires, guide catheters, angiographic catheters and microcatheters are described elsewhere and are regularly used in cath lab procedures. It is assumed in the descriptions below that these products and methods are employed in conjunction with the device and methods of this invention and do not need to be described in detail.


The following detailed description is merely exemplary in nature and is not intended to limit the invention or the application and uses of the invention. Although the description of the invention is in many cases in the context of treatment of intracranial arteries, the invention may also be used in other body passageways as previously described.


A common theme across many of the disclosed designs is a dual layer construction in which the device comprises an outer expandable member within which runs an inner expandable member, both members being directly or indirectly connected to an elongate shaft, and a distal net or scaffold configured at the distal end of the device to prevent the escape of clot fragments. This distal net may be appended to either the shaft, the inner or the outer members or to several of these. A range of designs are envisaged for each of these elements as described throughout this document, and it is intended that any of these elements could be used in conjunction with any other element, although to avoid repetition they are not shown in every possible combination.


Both the inner and outer expandable members are desirably made from a material capable of recovering its shape automatically once released from a highly strained delivery configuration. A superelastic material such as Nitinol or an alloy of similar properties is particularly suitable. The material could be in many forms such as wire or strip or sheet or tube. A particularly suitable manufacturing process is to laser cut a Nitinol tube and then heat set and electropolish the resultant structure to create a framework of struts and connecting elements. This framework can be any of a huge range of shapes as disclosed herein and may be rendered visible under fluoroscopy through the addition of alloying elements (such as Platinum for example) or through a variety of other coatings or marker bands.


The inner expandable member may in some cases form a generally tubular structure and is ideally configured to expand to a lesser diameter than that of the smallest vessel in which it is intended to be used. In the case of a generally non-tapered inner member this diameter is typically less than 50% that of the outer expandable member and may be as low as 20% or less of the outer member diameter.



FIGS. 1a and 1b show views from slightly different angles and orientations of one embodiment of a clot retrieval device of the present invention. The clot retrieval device 1 has an elongate shaft 6 having a distal end that extends interior of the artery and a proximal end that extends exterior of the artery, a clot engaging portion configured at the distal end of the elongate shaft 6 having an outer expandable member 2 comprising multiple expandable segments 26, and an inner expandable member 3 to facilitate restoration of blood flow through clot immediately after the clot retrieval device 1 is deployed at an obstructive site. The outer member 2 and inner expandable member 3 comprises a collapsed configuration for delivery and an expanded configuration for clot retrieval, flow restoration and fragmentation protection. In one embodiment the inner expandable member comprises a generally tubular body section. Outer member 2 comprises multiple inlet openings 22 through which clot can pass into an inner reception space 11 which is provided between the outer and inner expandable members. The outer expandable member 2 and the inner expandable member 3 are connected to the elongate shaft 6 at a proximal joint 12. The device also comprises a distal tip 8 which is appended to a distal joint 9 at the distal end of distal expandable segment 24. The distal portion of the inner expandable member is joined to that of the outer expandable member at distal joint 9.


The closed end of the distal expandable segment 28 prevents the egress of clot or clot fragments that have entered the reception space 11 between the inner and outer members. The expanded distal struts 10 of the inner member act as an additional three dimensional filter in combination with the closed distal end of the outer member 2 to further prevent the egress of clot or clot fragments. In certain embodiments this distal section may comprise fibre attachment points such as eyelets 87 or other fibre attachment features and fibres may be connected to the distal section at these attachment points to create a distal net.


The inner and outer members are preferably made of a super-elastic or pseudo-elastic material such as Nitinol or another such alloy with a high recoverable strain. Shaft 6 may be a tapered wire shaft, and may be made of stainless steel, MP35N, Nitinol or other material of a suitably high modulus and tensile strength. Shaft 6 has a coil 4 adjacent its distal end and proximal of the outer member 2 and inner expandable member 3. This coil 4 may be metallic and may be formed from stainless steel or from a more radiopaque material such as platinum or gold for example or an alloy of such a material. In another embodiment the coil 4 may be coated with a low friction material or have a polymeric jacket positioned on the outer surface of the coil.



FIG. 1c shows a close-up view of the area of the device highlighted by dashed elipse 83 in FIG. 1a. Proximal radiopaque markers 82 are positioned at the distal end of struts 20 just proximal to two proximal crowns 81. This position is advantageous because it denotes the start of the fully expanded diameter of the device (as can be seen more clearly in FIG. 1b), which is the portion of the device that is most desirable to deploy under the clot for optimal grip of the clot. Thus these markers can be used to indicate to the physician where to deploy the device relative to the clot for an optimal result. Positioning these markers just proximal of crowns 81 provides greater space to make these markers as large (and thus visible) as possible. If positioned distal of crowns 81 the markers would be competing for space (when collapsed within a microcatheter) with struts 44 and 51 and would hence need to be made very small to avoid compromising the profile or deliverability of the device.



FIG. 2a shows a plan view and FIG. 2b shows an elevation of the outer member 2. Outer member 2 comprises multiple expandable segments 26 interspersed with inlet openings 22 and terminating with a distal expandable basket segment 28. Proximal struts 20 are connected at their proximal ends to a collar 12 and at their distal ends to the first of expandable segments 26. The proximal struts 20 may have a tapered profile to ensure a gradual stiffness transition from the shaft 6 to the clot engagement section of the device. Each expandable segment 26 is connected to the segment distal to it by twin connecting arms 29, which run from proximal junctions 39 to distal junctions 40. In one embodiment these connecting arms comprise generally straight struts running parallel to the central axis of the device. In other embodiments these connecting arms may comprise a plurality of struts configured in one or more cells, or may comprise curved or spiral arms. These connecting arms 29 thus act as hinge elements which allow the device to flex between expandable segments without compromising the ability of the segments to remain expanded and well apposed to the vessel wall. The region between each adjacent expandable segment comprises a pair of inlet mouths 22 through which clot may pass and enter the reception space 11 defined by the region between the inner and outer members. The inlet mouths 22 provide the added benefit of allowing the outer member 2 when retracted to apply a force to the clot in a direction substantially parallel to the direction in which the clot is to be pulled from the vessel (i.e. substantially parallel to the central axis of the vessel). This means that the outward radial force applied to the vasculature may be kept to a minimum, which in turn means that the action of the clot retrieval device 1 on the clot does not serve to increase the force required to dislodge the clot from the vessel, thus protecting delicate cerebral vessels from harmful radial and tensile forces. In one embodiment the connecting arms 29 between each expandable segment are substantially aligned with one another, while in another embodiment the connecting arms between a first pair of expandable segments may be positioned 90° to a second pair.


Each expandable segment 26 comprises a proximal ring of connected struts 84 and a plurality of distal “leaflets” 85. Each leaflet comprises a pair of struts terminating in a distal crown 86 to which no further elements are connected. The connected ring of struts 84 provides the segment with the radial force to open and expand when deployed under a clot. The leaflets 85 are able to deflect (like trapdoors) to allow clot to slide into the inlet openings 22. The combination of leaflets and hinge elements 29 allows the device to retain its expanded shape and remain in contact with the vessel wall as the device is retracted around bends and past branch vessels. During this retraction process the leaflets act to prevent clot from escaping from the device, closing the trapdoor and gently contacting the vessel wall.


One or more expandable members may comprise marker bands or radiopaque features such as gold or platinum marker or coils. In this embodiment three radiopaque markers 25 are shown fixed in eyelets 87 of the distal expandable member 28. The gold marker is positioned to indicate to the user the distal end of the barrel section of the outer member to aid in accuracy of deployment.



FIG. 2c shows a developed view of the outer expandable member in its unexpanded state, such as when it is held within the lumen of a microcatheter for example. In one embodiment the outer expandable member is formed from a tube by laser cutting (or a similar material removal process) slots and removing material from the tube. In one embodiment this tube is of a very small diameter—much smaller than that of the expanded diameter of the outer expandable member, and ideally smaller than the inner lumen (diameter) of the microcatheter through which the device is designed to be delivered. Such a device would have a developed cut pattern similar to that of FIG. 2c in its unexpanded state. Cutting from such a small tube diameter creates significant manufacturing challenges, but has significant advantages also in that it allows the distal end of the device to be easily formed into a conical “capture basket” shape and it allows proximal collar 12 to comprise a cylinder that will fit within the microcatheter lumen and can be very securely joined to elongate shaft 6.



FIG. 2d shows a close up view of the proximal portion of the developed view shown in FIG. 2c. Proximal radiopaque markers 82 are located within eyelets 88 at the distal end of struts 20 just proximal to the two proximal crowns 81. This position is advantageous because it denotes the start of the fully expanded diameter of the device, which is the portion of the device that is most desirable to deploy under the clot for optimal grip of the clot. Thus these markers can be used to indicate to the physician where to deploy the device relative to the clot for an optimal result. Markers on other commercially available devices are generally positioned proximal, distal or within areas of the device that are intended to be deployed under the clot, and thus serve to indicate the location of the device without providing useful information to the user regarding optimal positioning of the device. The inventors have carried out extensive research into the ideal position to deploy such a device relative to the clot, and have discovered that aligning the proximal edge of the “working length” of the device with the proximal face of the clot gives the best recanalisation results. Hence these markers 82 are positioned at the proximal edge of this “working length”, which is the length of the device that comprises clot scaffolding regions and clot inlet mouths and expands to the largest diameter when unconstrained.



FIG. 3a shows a side view of the inner expandable member 3. The inner expandable member 3 comprises a collapsed configuration for delivery and an expanded configuration for flow restoration and fragmentation protection. The inner expandable member 3 may comprise an elastic or super-elastic or shape-memory metallic structure and may further comprise a polished surface such as an electro-polished surface. The inner expandable member 3 is configured so as to provide a flow lumen through the device 1 to facilitate the immediate restoration of blood flow past the clot upon deployment. In one embodiment the inner expandable member 3 is configured to scaffold said flow lumen through the clot to prevent the liberation of fragments which might otherwise lodge in the distal vasculature. Inner expandable member 3 comprises a generally cylindrical section of interconnected struts 31, which is connected at its proximal end by strut 34 to partial collar 13. The distal end of the inner expandable member 3 consists of an expansile section formed from expanded struts 10 which have a diameter greater than that of the body section of the inner expandable member 3. These expanded struts are connected to a coil section 18 which in this embodiment is laser cut from the tubing that the inner expandable member 3 is also cut from during processing. The distal end of the coil 18 on the inner expandable member 3 is bonded to the distal collar of the outer member 2 by adhesive.


The outer member 2 and the inner expandable member 3 are joined at the proximal and distal ends during assembly thereof to minimise tension within the members during use, the length of the outer member 2 should be substantially the same as the length of the inner expandable member 3 in the freely expanded configuration and the loaded configuration. The expanded struts 10 of the inner expandable member 3 elongate during loading so that the lengths of the inner and outer members are equal when fully loaded in a microcatheter. Length differentials between the inner expandable member 3 and the outer member 2 can still occur when the device is deployed in a small vessel or during the loading or deployment process. The coil 18 at the distal end of the inner expandable member 3 can accommodate minor length differentials by stretching without applying significant tensile or compressive forces to the device. In another embodiment this coil could be formed separately to the inner expandable member 3 and then be assembled to it. The coil could be formed from a stainless steel material, a polymer or from a more radiopaque metal such as gold or platinum or an alloy of such a material. The coil could also be replaced with a longitudinal length of an elastic material such as a low modulus polymer or elastomer.



FIG. 3b shows a developed view of the inner expandable member 3 in its unexpanded state, such as when it is held within the lumen of a microcatheter for example. In one embodiment the inner expandable member is formed from a tube by laser cutting (or a similar material removal process) slots and removing material from the tube. In one embodiment this tube is of a very small diameter—much smaller than that of its expanded diameter and ideally smaller than the inner lumen (diameter) of the microcatheter through which the device is designed to be delivered. Such a device would have a developed cut pattern similar to that of FIG. 3b in its unexpanded state.



FIG. 3c shows a detail view of the region of FIG. 3b highlighted by elipse 89. In this close up view it can be seen that each cell of the inner member ends in a crown 90, to which is appended a connector element 91. Each of these connector elements then diverges at a first crown 92 into another pair of strut elements. One of each pair of these strut elements then converges with and is joined to one of an adjacent pair of strut elements at a second crown 93. This pattern is continued along the body of the member to maintain a constant number of cell elements around the circumference. In order to increase the number of cells around the circumference (to further reduce the porosity in a certain portion for example) a change in pattern is required. This is achieved by taking one pair of strut elements 94 and diverging each strut into a further pair of short strut elements 95. Thus four short strut elements 95 are created, and adjacent short strut elements converge and are connected at crown 96, while the other short strut elements 97 are connected to adjacent long struts 98 at crowns 99.



FIGS. 4a-4f shows a method of use of a device of this invention. A guidewire 103 and microcatheter 102 are inserted in the artery 100 and are advanced across the obstructive clot 101 using conventionally known techniques. When the microcatheter 102 is positioned distal to the occlusive clot 101, the guidewire 103 is removed from the artery 100 to allow the clot retrieval device 110 be advanced through the microcatheter 102. The device 110 is advanced in a collapsed configuration within the microcatheter 102 until the proximal radiopaque markers (not shown in FIG. 4c) of the device 110 align with the proximal margin 105 of the clot 101 under fluoroscopy.


The microcatheter 102 is retracted while the position of device 110 is maintained static to deploy the clot retrieval device 110 across the clot 101. On deployment, the distal end 120 of the device 110 is preferably positioned distal of the clot 101. The device 110 expands so that the outer member 121 engages with the occlusive clot to facilitate clot retrieval from the vessel, and the inner tubular member 122 expands to provide a flow channel to restore blood flow in a controlled manner through the occlusive clot 101 to the vasculature distal of the occlusion. The inner channel 122 may also engage the clot 101 to provide additional grip for dislodgement. The device 110 may be allowed to incubate for a period of time within the clot 101 if desired, as controlled flow has been restored through the inner tubular member 122. FIG. 4e also shows the proximal radiopaque markers 123 aligned with the proximal margin 105 of the clot after device deployment from the microcatheter 102.


Retracting the device 110 dislodges the clot 101 from its position in the artery 100 and further withdrawal of the device retrieves the clot 101 until it can be retrieved into the guide catheter or introducer sheath 130. FIG. 4f illustrates the clot 140 engaged with the device 110 during retrieval into the guide catheter 130. The clot 140 is partially located in the inlet openings 141 of the device 110 and also partially located in the reception space 142 defined by the region between the inner and outer members. Clot fragments 143 are shown trapped in the distal end of the device 110 where the closed end of the outer member 144 and the expanded struts of the inner member 145 have prevented the fragments from being released in the blood flow. Flow occlusion, aspiration and other standard techniques may be used during the clot retrieval process. The device 110 may be rinsed in saline and gently cleaned before reloading in the insertion tool (not shown). The device 110 may be reintroduced into the microcatheter to be redeployed in additional segments of occlusive clot, if required.



FIG. 5 shows a side view of a clot retrieval device 200 of this invention similar in design and construction to device 1 of FIG. 1, but with a different outer member design. Outer member 201 comprises a series of expandable segments 202, separated by a series of inlet openings 203. In this embodiment the inlet openings increase in size along the length of the device, so that the proximal inlet opening is the smallest and the distal most one the largest. In other embodiments the inlet openings may be varied in size and position in other ways, such as alternating small/large or randomly sized. The device further comprises an inner expandable member 204, similar to other inner expandable members previously described herein.



FIG. 6 shows a side view of another clot retrieval device 250 of this invention similar to device 200 of FIG. 5, but without an inner expandable member. In this embodiment the inlet openings 251 of the outer member 252 decrease in size along the length of the device, so that the proximal inlet opening 253 is the largest and the distal most opening 254 the smallest. In other embodiments the inlet openings may be varied in size and position in other ways, such as alternating small/large or randomly sized.



FIG. 7 shows a side view of another clot retrieval device 280 of this invention similar to device 1 of FIG. 1. In this embodiment the inlet openings of the outer member decrease in size along the length of the device, so that the proximal inlet opening 281 is the largest and the distal most one 282 the smallest. The inner expandable member 283 is generally tubular and tapers from a small diameter proximally to a larger diameter distally. This combination of decreasing inlet opening size and increasing inner member diameter means that an embolus or clot entering a proximal inlet opening of the device is demobilised and prevented from migrating distally through the device and escaping from a more distal opening. In the embodiment shown the diameter of the outer member 284 is tapered in the opposite direction to that of the inner member, so that the proximal expandable segment 285 is larger in diameter than adjacent segment 286. This allows the device to conform well to the natural distal tapering of typical arterial vessels. In another embodiment the main body of the outer member may be generally constant in diameter. In yet another embodiment the main body of the outer member may taper in the opposite direction—with the distal most segment being largest in diameter so as to provide optimally protection against distal embolization as the device is retracted proximally into increasingly larger vessels.


It will be apparent from the foregoing description that, while particular embodiments of the present invention have been illustrated and described, various modifications can be made without departing from the spirit and scope of the invention. For example, while the embodiments described herein refer to particular features, the invention includes embodiments having different combinations of features. The invention also includes embodiments that do not include all of the specific features described.


The invention is not limited to the embodiments hereinbefore described which may be varied in construction and detail.

Claims
  • 1. A clot retrieval device for removing occlusive clot from a blood vessel, the device comprising: A tapered inner elongate body comprising a collapsed delivery configuration and an expanded deployed configuration;an outer elongate body at least partially overlying the inner elongate body, the outer elongate body being expandable to a radial extent which is greater than the radial extent of the inner body in the deployed configuration to define a clot reception space;wherein the outer elongate body comprises a plurality of clot inlet openings and a plurality of clot engaging regions, wherein the clot engaging regions are adapted, on engagement with clot, to urge clot towards the clot receiving openings and into the reception space between the outer elongate body and the inner elongate body;wherein there is a gradient in the size of the clot inlet openings in the outer body along the length of the device, the gradient being opposite to the direction of the taper of the inner elongate body; andwherein the radial force profile of the device varies along the length of the device.
  • 2. The device as claimed in claim 1 wherein the radial force at a distal end of the device is lower than that at a middle section of the device.
  • 3. The device as claimed in claim 1 wherein the radial force at a distal end of the device is lower than that of a middle section and a proximal section of the device.
  • 4. The device as claimed in claim 1 wherein the device comprises a plurality of segments and the radial force of one segment is different than the radial force of at least one other segment.
  • 5. The device as claimed in claim 4 wherein the difference in radial force between the segments is less than 20%.
  • 6. The device as claimed in claim 4 wherein the radial force increases along the length of the device from proximal to distal.
  • 7. The device as claimed in claim 4 wherein the radial force decreases along the length of the device from proximal to distal.
  • 8. The device as claimed in claim 4 wherein the radial force of a mid segment is greater than the radial force of a distal segment.
  • 9. The device as claimed in claim 4 wherein the radial force of a mid segment is greater than that of a proximal segment and the distal segment.
  • 10. The device as claimed in claim 1, wherein the outer body comprises a plurality of segments, wherein a segment comprises a proximal ring of closed cells having a first radial force to which are connected at least one floating cell or leaflet having a second radial force which is less than the first radial force.
  • 11. The device as claimed in claim 10 wherein the floating cell or leaflet comprises a distal apex which is not connected to an adjacent distal segment.
  • 12. The device as claimed in claim 10 wherein the second radial force is from 20% to 80% lower than the first radial force.
  • 13. The device as claimed in claim 1, wherein the clot inlet openings of the outer body differ along the length of the device wherein clot inlet openings in a proximal region of the device are smaller than clot inlet openings in a distal region of the device.
  • 14. The device as claimed in claim 1, wherein the clot inlet openings of the outer body differ along the length of the device wherein the clot inlet openings in a middle section of the device are smaller than those in a more proximal and/or a more distal region of the device.
  • 15. The device as claimed in claim 1, wherein the clot inlet openings of the outer body differ along the length of the device wherein the clot inlet openings in a middle section of the device are larger than those in a more proximal and/or a more distal region of the device.
  • 16. The device as claimed in claim 1, wherein there is a gradient of the size of the clot inlet openings along the length of the device wherein the gradient increases from proximal to distal.
  • 17. The device as claimed in claim 1, wherein there is a gradient of the size of the clot inlet openings along the length of the device wherein the gradient decreases from proximal to distal.
  • 18. The device as claimed in claim 1, wherein there is a gradient of the size of the clot inlet openings along the length of the device wherein the inner elongate body is tapered, wherein the taper of the inner elongate body is opposite to the gradient of the clot inlet openings in the outer body.
  • 19. The device as claimed in claim 1 wherein the outer elongate member comprises a framework formed by struts and crowns and wherein proximal radiopaque markers are located at a distal end of struts which are proximally adjacent to proximal crowns.
  • 20. A clot retrieval device for removing occlusive clot from a blood vessel, the device comprising: a tapered inner elongate body comprising a collapsed delivery configuration and an expanded deployed configuration;an outer elongate body at least partially overlying the inner elongate body;the outer elongate body being expandable to a radial extent which is greater than the radial extent of the inner body in the deployed configuration to define a clot reception space;the outer elongate body comprising a plurality of clot receiving openings and a plurality of clot engaging regions, wherein the clot engaging regions are adapted, on engagement with clot, to urge clot towards the clot receiving openings and into the reception space between the outer elongate body and the inner elongate body,wherein the outer elongate member comprises a framework formed by struts and crowns and wherein proximal radiopaque markers are located at a distal end of struts which are proximally adjacent to proximal crowns; andwherein there is a gradient in the size of the clot receiving openings in the outer elongate body along the length of the device, the gradient being opposite to the direction of the taper of the inner elongate body.
CROSS REFERENCE TO RELATED APPLICATIONS

This is a U.S. national phase application under 35 U.S.C. § 371 of International Patent Application No. PCT/EP2017/072030, filed Sep. 1, 2017, and claims benefit of priority to U.S. Provisional Patent Application No. 62/383,905, filed Sep. 6, 2016. The entire contents of these applications are hereby incorporated by reference.

PCT Information
Filing Document Filing Date Country Kind
PCT/EP2017/072030 9/1/2017 WO 00
Publishing Document Publishing Date Country Kind
WO2018/046408 3/15/2018 WO A
US Referenced Citations (862)
Number Name Date Kind
2828147 Peiffer Mar 1958 A
3361460 Jansen Jan 1968 A
4455717 Gray Jun 1984 A
4611594 Grayhack et al. Sep 1986 A
4612931 Dormia Sep 1986 A
4793348 Palmaz Dec 1988 A
4873978 Ginsburg Oct 1989 A
5011488 Ginsburg Apr 1991 A
5084065 Weldon et al. Jan 1992 A
5092839 Kipperman Mar 1992 A
5100423 Fearnot Mar 1992 A
5102415 Guenther et al. Apr 1992 A
5108419 Reger et al. Apr 1992 A
5122136 Guglielmi et al. Jun 1992 A
5163951 Pinchuk et al. Nov 1992 A
5171233 Amplatz et al. Dec 1992 A
5171259 Inoue Dec 1992 A
5217441 Shichman Jun 1993 A
5234437 Sepetka Aug 1993 A
5236447 Kubo et al. Aug 1993 A
5330482 Gibbs et al. Jul 1994 A
5387219 Rappe Feb 1995 A
5387226 Miraki Feb 1995 A
5449372 Schmaltz et al. Sep 1995 A
5499985 Hein et al. Mar 1996 A
5538512 Zenzon et al. Jul 1996 A
5538515 Kafry et al. Jul 1996 A
5549626 Miller et al. Aug 1996 A
5558652 Henke Sep 1996 A
5609627 Goicoechea et al. Mar 1997 A
5624461 Mariant Apr 1997 A
5639277 Mariant et al. Jun 1997 A
5639278 Dereume et al. Jun 1997 A
5645558 Horton Jul 1997 A
5653605 Woehl et al. Aug 1997 A
5658296 Bates et al. Aug 1997 A
5665117 Rhodes Sep 1997 A
5695519 Summers et al. Dec 1997 A
5709704 Nott et al. Jan 1998 A
5713853 Clark et al. Feb 1998 A
5769871 Mers Kelly et al. Jun 1998 A
5769884 Solovay Jun 1998 A
5779686 Sato et al. Jul 1998 A
5779716 Cano et al. Jul 1998 A
5800519 Sandock Sep 1998 A
5810874 Lefebvre Sep 1998 A
5814064 Daniel et al. Sep 1998 A
5827304 Hart Oct 1998 A
5853422 Huebsch et al. Dec 1998 A
5855598 Pinchuk Jan 1999 A
5893869 Barnhart et al. Apr 1999 A
5895398 Wensel et al. Apr 1999 A
5897567 Ressemann et al. Apr 1999 A
5904698 Thomas et al. May 1999 A
5911702 Romley et al. Jun 1999 A
5911725 Boury Jun 1999 A
5919126 Armini Jul 1999 A
5931509 Bartholomew Aug 1999 A
5935139 Bates Aug 1999 A
5947995 Samuels Sep 1999 A
6063113 Kavteladze et al. May 2000 A
6066149 Samson et al. May 2000 A
6066158 Engelson et al. May 2000 A
6093196 Okada Jul 2000 A
6093199 Brown et al. Jul 2000 A
6096053 Bates Aug 2000 A
6099534 Bates et al. Aug 2000 A
6099559 Nolting Aug 2000 A
6102932 Kurz Aug 2000 A
6106548 Roubin et al. Aug 2000 A
6129739 Khosravi Oct 2000 A
6143022 Shull et al. Nov 2000 A
6146404 Kim et al. Nov 2000 A
6156064 Chouinard Dec 2000 A
6165194 Denardo Dec 2000 A
6165199 Barbut Dec 2000 A
6168604 Cano Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6174318 Bates et al. Jan 2001 B1
6179861 Khosravi et al. Jan 2001 B1
6203561 Ramee et al. Mar 2001 B1
6214026 Lepak et al. Apr 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6231597 Deem et al. May 2001 B1
6238412 Dubrul et al. May 2001 B1
6245012 Kleshinski Jun 2001 B1
6245087 Addis Jun 2001 B1
6251122 Tsukernik Jun 2001 B1
6254571 Hart Jul 2001 B1
6264663 Cano Jul 2001 B1
6267777 Bosma et al. Jul 2001 B1
6290710 Cryer et al. Sep 2001 B1
6312444 Barbut Nov 2001 B1
6315778 Gambale et al. Nov 2001 B1
6325815 Kusleika et al. Dec 2001 B1
6325819 Pavcnik et al. Dec 2001 B1
6334864 Amplatz et al. Jan 2002 B1
6336934 Gilson et al. Jan 2002 B1
6346116 Brooks et al. Feb 2002 B1
6348056 Bates et al. Feb 2002 B1
6350271 Kurz et al. Feb 2002 B1
6355057 DeMarais et al. Mar 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6364895 Greenhalgh Apr 2002 B1
6375668 Gifford et al. Apr 2002 B1
6375670 Greenhalgh Apr 2002 B1
6383205 Samson et al. May 2002 B1
6383206 Gillick et al. May 2002 B1
6391037 Greenhalgh May 2002 B1
6402771 Palmer et al. Jun 2002 B1
6416541 Denardo Jul 2002 B2
6425909 Dieck et al. Jul 2002 B1
6428558 Jones et al. Aug 2002 B1
6432122 Gilson et al. Aug 2002 B1
6436112 Wensel et al. Aug 2002 B2
6458139 Palmer et al. Oct 2002 B1
6485497 Wensel et al. Nov 2002 B2
6485501 Green Nov 2002 B1
6485502 Don Michael et al. Nov 2002 B2
6488701 Nolting et al. Dec 2002 B1
6511492 Rosenbluth et al. Jan 2003 B1
6530935 Wensel et al. Mar 2003 B2
6530939 Hopkins et al. Mar 2003 B1
6540768 Diaz et al. Apr 2003 B1
6544279 Hopkins et al. Apr 2003 B1
6551341 Boylan et al. Apr 2003 B2
6551342 Shen et al. Apr 2003 B1
6575996 Denison et al. Jun 2003 B1
6575997 Palmer et al. Jun 2003 B1
6582448 Boyle et al. Jun 2003 B1
6585756 Strecker Jul 2003 B1
6589265 Palmer et al. Jul 2003 B1
6592607 Palmer et al. Jul 2003 B1
6592614 Lenker et al. Jul 2003 B2
6592616 Stack et al. Jul 2003 B1
6598265 Lee Jul 2003 B2
6602265 Dubrul et al. Aug 2003 B2
6602271 Adams et al. Aug 2003 B2
6602272 Boylan et al. Aug 2003 B2
6605102 Mazzocchi et al. Aug 2003 B1
6610077 Hancock et al. Aug 2003 B1
6616679 Khosravi et al. Sep 2003 B1
6632241 Hancock et al. Oct 2003 B1
6638245 Miller et al. Oct 2003 B2
6638293 Makower et al. Oct 2003 B1
6641590 Palmer et al. Nov 2003 B1
6656218 Denardo et al. Dec 2003 B1
6660021 Palmer et al. Dec 2003 B1
6663650 Sepetka et al. Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6685722 Rosenbluth et al. Feb 2004 B1
6692504 Kurz et al. Feb 2004 B2
6692508 Wensel et al. Feb 2004 B2
6692509 Wensel et al. Feb 2004 B2
6695858 Dubrul et al. Feb 2004 B1
6702782 Miller et al. Mar 2004 B2
6712834 Yassour et al. Mar 2004 B2
6726701 Gilson et al. Apr 2004 B2
6726703 Broome et al. Apr 2004 B2
6730104 Sepetka et al. May 2004 B1
6783528 Vincent-Prestigiacomo Aug 2004 B2
6783538 McGuckin, Jr. et al. Aug 2004 B2
6824545 Sepetka et al. Nov 2004 B2
6855155 Denardo et al. Feb 2005 B2
6878163 Denardo et al. Apr 2005 B2
6890340 Duane May 2005 B2
6913612 Palmer et al. Jul 2005 B2
6913618 Denardo et al. Jul 2005 B2
6939361 Kleshinski Sep 2005 B1
6953472 Palmer et al. Oct 2005 B2
6989019 Mazzocchi et al. Jan 2006 B2
6989021 Bosma et al. Jan 2006 B2
6994718 Groothuis et al. Feb 2006 B2
7004954 Voss et al. Feb 2006 B1
7004955 Shen et al. Feb 2006 B2
7004956 Palmer et al. Feb 2006 B2
7008434 Kurz et al. Mar 2006 B2
7033376 Tsukernik Apr 2006 B2
7041116 Goto et al. May 2006 B2
7048758 Boyle et al. May 2006 B2
7052500 Bashiri et al. May 2006 B2
7058456 Pierce Jun 2006 B2
7063707 Bose et al. Jun 2006 B2
7083633 Morrill et al. Aug 2006 B2
7083822 Brightbill Aug 2006 B2
7094249 Broome et al. Aug 2006 B1
7097653 Freudenthal et al. Aug 2006 B2
7101380 Khachin et al. Sep 2006 B2
7172614 Boyle et al. Feb 2007 B2
7175655 Molaei Feb 2007 B1
7179273 Palmer et al. Feb 2007 B1
7185922 Takayanagi et al. Mar 2007 B2
7220271 Clubb et al. May 2007 B2
7226464 Gamer et al. Jun 2007 B2
7229472 DePalma et al. Jun 2007 B2
7241304 Boyle et al. Jul 2007 B2
7288112 Denardo et al. Oct 2007 B2
7300458 Henkes et al. Nov 2007 B2
7306618 Demond et al. Dec 2007 B2
7314483 Landau et al. Jan 2008 B2
7316692 Huffmaster Jan 2008 B2
7323001 Clubb et al. Jan 2008 B2
7331976 McGuckin, Jr. et al. Feb 2008 B2
7344550 Carrison et al. Mar 2008 B2
7399308 Borillo et al. Jul 2008 B2
7410491 Hopkins et al. Aug 2008 B2
7425215 Boyle et al. Sep 2008 B2
7452496 Brady et al. Nov 2008 B2
7491215 Vale et al. Feb 2009 B2
7491216 Brady Feb 2009 B2
7510565 Gilson et al. Mar 2009 B2
7534252 Sepetka et al. May 2009 B2
7556636 Mazzocchi et al. Jul 2009 B2
7582111 Krolik et al. Sep 2009 B2
7594926 Linder et al. Sep 2009 B2
7604649 McGuckin, Jr. et al. Oct 2009 B2
7604650 Bergheim Oct 2009 B2
7609649 Bhandari et al. Oct 2009 B1
7618434 Santa et al. Nov 2009 B2
7662165 Gilson et al. Feb 2010 B2
7670356 Mazzocchi et al. Mar 2010 B2
7678123 Chanduszko Mar 2010 B2
7691121 Rosenbluth et al. Apr 2010 B2
7691124 Balgobin Apr 2010 B2
7708770 Linder et al. May 2010 B2
7717929 Fallman May 2010 B2
7736385 Agnew Jun 2010 B2
7758606 Streeter et al. Jul 2010 B2
7758611 Kato Jul 2010 B2
7766934 Pal et al. Aug 2010 B2
7771452 Pal et al. Aug 2010 B2
7780694 Palmer et al. Aug 2010 B2
7780700 Frazier et al. Aug 2010 B2
7811305 Balgobin et al. Oct 2010 B2
7815659 Conlon et al. Oct 2010 B2
7819893 Brady et al. Oct 2010 B2
7828815 Mazzocchi et al. Nov 2010 B2
7828816 Mazzocchi et al. Nov 2010 B2
7833240 Okushi et al. Nov 2010 B2
7842053 Chanduszko et al. Nov 2010 B2
7846175 Bonnette et al. Dec 2010 B2
7846176 Gilson et al. Dec 2010 B2
7850708 Pal Dec 2010 B2
7883516 Huang et al. Feb 2011 B2
7887560 Kusleika Feb 2011 B2
7901426 Gilson et al. Mar 2011 B2
7914549 Morsi Mar 2011 B2
7922732 Mazzocchi et al. Apr 2011 B2
7927784 Simpson Apr 2011 B2
7931659 Bose et al. Apr 2011 B2
7998165 Huffmaster Aug 2011 B2
8002822 Glocker et al. Aug 2011 B2
8021379 Thompson et al. Sep 2011 B2
8021380 Thompson et al. Sep 2011 B2
8043326 Hancock et al. Oct 2011 B2
8048151 OBrien et al. Nov 2011 B2
8052640 Fiorella et al. Nov 2011 B2
8057497 Raju et al. Nov 2011 B1
8057507 Horan et al. Nov 2011 B2
8066757 Ferrera et al. Nov 2011 B2
8070791 Ferrera et al. Dec 2011 B2
8088140 Ferrera et al. Jan 2012 B2
8100935 Rosenbluth et al. Jan 2012 B2
8109941 Richardson Feb 2012 B2
8118829 Carrison et al. Feb 2012 B2
8118856 Schreck et al. Feb 2012 B2
8123769 Osborne Feb 2012 B2
8137377 Palmer et al. Mar 2012 B2
8142422 Makower et al. Mar 2012 B2
8142442 Palmer et al. Mar 2012 B2
8182508 Magnuson et al. May 2012 B2
8187298 Pal May 2012 B2
8246641 Osborne et al. Aug 2012 B2
8246672 Osborne Aug 2012 B2
8252017 Paul, Jr. et al. Aug 2012 B2
8252018 Valaie Aug 2012 B2
8262689 Schneiderman et al. Sep 2012 B2
8285668 Kaiser Oct 2012 B2
8287538 Brenzel et al. Oct 2012 B2
8298257 Sepetka et al. Oct 2012 B2
RE43882 Hopkins et al. Dec 2012 E
8357178 Grandfield et al. Jan 2013 B2
8357179 Grandfield et al. Jan 2013 B2
8357180 Feller, III et al. Jan 2013 B2
8357893 Xu et al. Jan 2013 B2
8361095 Osborne Jan 2013 B2
8361110 Chanduszko Jan 2013 B2
8366663 Fiorella et al. Feb 2013 B2
8409215 Sepetka et al. Apr 2013 B2
8414482 Belson Apr 2013 B2
8414543 McGuckin, Jr. et al. Apr 2013 B2
8419748 Valaie Apr 2013 B2
8460312 Bose et al. Jun 2013 B2
8460313 Huffmaster Jun 2013 B2
8486104 Samson et al. Jul 2013 B2
8529596 Grandfield et al. Sep 2013 B2
8545526 Martin et al. Oct 2013 B2
8574262 Ferrera et al. Nov 2013 B2
8574915 Zhang et al. Nov 2013 B2
8579915 French et al. Nov 2013 B2
8585713 Ferrera et al. Nov 2013 B2
8608761 Osborne et al. Dec 2013 B2
8679142 Slee et al. Mar 2014 B2
8690907 Janardhan Apr 2014 B1
8696622 Fiorella et al. Apr 2014 B2
8702652 Fiorella et al. Apr 2014 B2
8702704 Shelton, IV et al. Apr 2014 B2
8702724 Olsen et al. Apr 2014 B2
8777919 Kimura et al. Jul 2014 B2
8777976 Brady et al. Jul 2014 B2
8777979 Shrivastava et al. Jul 2014 B2
8784434 Rosenbluth et al. Jul 2014 B2
8784441 Rosenbluth et al. Jul 2014 B2
8795305 Martin et al. Aug 2014 B2
8795317 Grandfield et al. Aug 2014 B2
8795345 Grandfield et al. Aug 2014 B2
8814892 Galdonik et al. Aug 2014 B2
8814925 Hilaire et al. Aug 2014 B2
8852205 Brady et al. Oct 2014 B2
8870941 Evans et al. Oct 2014 B2
8900265 Ulm, III Dec 2014 B1
8920358 Levine et al. Dec 2014 B2
8939991 Krolik et al. Jan 2015 B2
8945143 Ferrera et al. Feb 2015 B2
8945160 Krolik et al. Feb 2015 B2
8945169 Pal Feb 2015 B2
8945172 Ferrera et al. Feb 2015 B2
8956399 Cam et al. Feb 2015 B2
8968330 Rosenbluth et al. Mar 2015 B2
9011481 Aggerholm et al. Apr 2015 B2
9039749 Shrivastava et al. May 2015 B2
9072537 Grandfield et al. Jul 2015 B2
9095342 Becking et al. Aug 2015 B2
9113936 Palmer et al. Aug 2015 B2
9119656 Bose et al. Sep 2015 B2
9138307 Valaie Sep 2015 B2
9155552 Ulm, III Oct 2015 B2
9161758 Figulla et al. Oct 2015 B2
9161766 Slee et al. Oct 2015 B2
9173668 Ulm, III Nov 2015 B2
9173688 Dosta Nov 2015 B2
9186487 Dubrul et al. Nov 2015 B2
9198687 Fulkerson et al. Dec 2015 B2
9204887 Cully et al. Dec 2015 B2
9211132 Bowman Dec 2015 B2
9232992 Heidner et al. Jan 2016 B2
9254371 Martin et al. Feb 2016 B2
9301769 Brady et al. Apr 2016 B2
9332999 Ray et al. May 2016 B2
9402707 Brady et al. Aug 2016 B2
9445829 Brady et al. Sep 2016 B2
9456834 Folk Oct 2016 B2
9532792 Galdonik et al. Jan 2017 B2
9532873 Kelley Jan 2017 B2
9533344 Monetti et al. Jan 2017 B2
9539011 Chen et al. Jan 2017 B2
9539022 Bowman Jan 2017 B2
9539122 Burke et al. Jan 2017 B2
9539382 Nelson Jan 2017 B2
9549830 Bruszewski et al. Jan 2017 B2
9554805 Tompkins et al. Jan 2017 B2
9561125 Bowman et al. Feb 2017 B2
9572982 Burnes et al. Feb 2017 B2
9579104 Beckham et al. Feb 2017 B2
9579484 Barnell Feb 2017 B2
9585642 Dinsmoor et al. Mar 2017 B2
9615832 Bose et al. Apr 2017 B2
9615951 Bennett et al. Apr 2017 B2
9622753 Cox Apr 2017 B2
9636115 Henry et al. May 2017 B2
9636439 Chu et al. May 2017 B2
9642639 Brady et al. May 2017 B2
9642675 Werneth et al. May 2017 B2
9655633 Leynov et al. May 2017 B2
9655645 Staunton May 2017 B2
9655898 Palepu et al. May 2017 B2
9655989 Cruise et al. May 2017 B2
9662129 Galdonik et al. May 2017 B2
9662238 Dwork et al. May 2017 B2
9662425 Lilja et al. May 2017 B2
9668898 Wong Jun 2017 B2
9675477 Thompson Jun 2017 B2
9675782 Connolly Jun 2017 B2
9676022 Ensign et al. Jun 2017 B2
9692557 Murphy Jun 2017 B2
9693852 Lam et al. Jul 2017 B2
9700262 Janik et al. Jul 2017 B2
9700399 Acosta-Acevedo Jul 2017 B2
9717421 Griswold et al. Aug 2017 B2
9717500 Tieu et al. Aug 2017 B2
9717502 Teoh et al. Aug 2017 B2
9724103 Cruise et al. Aug 2017 B2
9724526 Strother et al. Aug 2017 B2
9750565 Bloom et al. Sep 2017 B2
9757260 Greenan Sep 2017 B2
9758606 Lambert et al. Sep 2017 B2
9764111 Gulachenski Sep 2017 B2
9770251 Bowman et al. Sep 2017 B2
9770577 Li et al. Sep 2017 B2
9775621 Tompkins et al. Oct 2017 B2
9775706 Peterson et al. Oct 2017 B2
9775732 Khenansho Oct 2017 B2
9788800 Mayoras, Jr. Oct 2017 B2
9795391 Saatchi et al. Oct 2017 B2
9801980 Karino et al. Oct 2017 B2
9808599 Bowman et al. Nov 2017 B2
9833252 Sepetka et al. Dec 2017 B2
9833304 Horan et al. Dec 2017 B2
9833604 Lam et al. Dec 2017 B2
9833625 Waldhauser et al. Dec 2017 B2
9901434 Hoffman Feb 2018 B2
9918720 Marchand et al. Mar 2018 B2
9939361 Gajji et al. Apr 2018 B2
10070878 Ma Sep 2018 B2
10201360 Vale et al. Feb 2019 B2
10292723 Brady et al. May 2019 B2
10299811 Brady et al. May 2019 B2
10363054 Vale et al. Jul 2019 B2
10376274 Farin et al. Aug 2019 B2
10390850 Vale et al. Aug 2019 B2
10617435 Vale et al. Apr 2020 B2
10722257 Skillrud et al. Jul 2020 B2
20010001315 Bates et al. May 2001 A1
20010016755 Addis Aug 2001 A1
20010037141 Yee et al. Nov 2001 A1
20010037171 Sato Nov 2001 A1
20010041909 Tsugita et al. Nov 2001 A1
20010049554 Ruiz et al. Dec 2001 A1
20010051810 Dubrul et al. Dec 2001 A1
20020004667 Adams et al. Jan 2002 A1
20020016609 Wensel et al. Feb 2002 A1
20020022859 Hogendijk Feb 2002 A1
20020026211 Khosravi et al. Feb 2002 A1
20020042627 Brady et al. Apr 2002 A1
20020049468 Streeter et al. Apr 2002 A1
20020052620 Barbut May 2002 A1
20020058911 Gilson et al. May 2002 A1
20020068954 Foster Jun 2002 A1
20020072764 Sepetka et al. Jun 2002 A1
20020082558 Samson et al. Jun 2002 A1
20020091407 Zadno-Azizi et al. Jul 2002 A1
20020095171 Belef Jul 2002 A1
20020123765 Sepetka et al. Sep 2002 A1
20020138094 Borillo et al. Sep 2002 A1
20020143349 Gifford, III et al. Oct 2002 A1
20020143362 Macoviak et al. Oct 2002 A1
20020156455 Barbut Oct 2002 A1
20020161393 Demond et al. Oct 2002 A1
20020165576 Boyle et al. Nov 2002 A1
20020173819 Leeflang et al. Nov 2002 A1
20020183787 Wahr et al. Dec 2002 A1
20020188276 Evans et al. Dec 2002 A1
20020188314 Anderson et al. Dec 2002 A1
20020193824 Boylan et al. Dec 2002 A1
20020198588 Armstrong et al. Dec 2002 A1
20030004536 Boylan et al. Jan 2003 A1
20030004538 Secrest et al. Jan 2003 A1
20030004540 Linder et al. Jan 2003 A1
20030004542 Wensel et al. Jan 2003 A1
20030009146 Muni et al. Jan 2003 A1
20030009191 Wensel et al. Jan 2003 A1
20030038447 Cantele Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030050663 Khachin et al. Mar 2003 A1
20030064151 Klinedinst Apr 2003 A1
20030108224 Ike Jun 2003 A1
20030114879 Euteneuer et al. Jun 2003 A1
20030125798 Martin Jul 2003 A1
20030130682 Broome et al. Jul 2003 A1
20030144687 Brady et al. Jul 2003 A1
20030144688 Brady et al. Jul 2003 A1
20030153158 Ho et al. Aug 2003 A1
20030153943 Michael et al. Aug 2003 A1
20030153944 Phung et al. Aug 2003 A1
20030163064 Vrba et al. Aug 2003 A1
20030163158 White Aug 2003 A1
20030171769 Barbut Sep 2003 A1
20030171771 Anderson et al. Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030187495 Cully et al. Oct 2003 A1
20030195537 Dubrul et al. Oct 2003 A1
20030195554 Shen et al. Oct 2003 A1
20030199917 Knudson et al. Oct 2003 A1
20030204202 Palmer et al. Oct 2003 A1
20030208224 Broome Nov 2003 A1
20030212430 Bose et al. Nov 2003 A1
20030236533 Wilson et al. Dec 2003 A1
20040064179 Linder et al. Apr 2004 A1
20040068288 Palmer et al. Apr 2004 A1
20040073243 Sepetka et al. Apr 2004 A1
20040079429 Miller et al. Apr 2004 A1
20040082962 Demarais et al. Apr 2004 A1
20040082967 Broome et al. Apr 2004 A1
20040088001 Bosma et al. May 2004 A1
20040093065 Yachia et al. May 2004 A1
20040098050 Foerster et al. May 2004 A1
20040133231 Maitland et al. Jul 2004 A1
20040133232 Rosenbluth et al. Jul 2004 A1
20040138692 Phung et al. Jul 2004 A1
20040153118 Clubb et al. Aug 2004 A1
20040199201 Kellett et al. Oct 2004 A1
20040215318 Kwitkin Oct 2004 A1
20040220663 Rivelli Nov 2004 A1
20050033248 Machida et al. Feb 2005 A1
20050033348 Sepetka et al. Feb 2005 A1
20050038447 Huffmaster Feb 2005 A1
20050038468 Panetta et al. Feb 2005 A1
20050043759 Chanduszko Feb 2005 A1
20050049619 Sepetka et al. Mar 2005 A1
20050049669 Jones et al. Mar 2005 A1
20050049670 Jones et al. Mar 2005 A1
20050055033 Leslie et al. Mar 2005 A1
20050055047 Greenhalgh Mar 2005 A1
20050058837 Farnworth et al. Mar 2005 A1
20050059995 Sepetka et al. Mar 2005 A1
20050085849 Sepetka et al. Apr 2005 A1
20050090779 Osypka Apr 2005 A1
20050090857 Kusleika et al. Apr 2005 A1
20050125024 Sepetka et al. Jun 2005 A1
20050149997 Wolozin et al. Jul 2005 A1
20050171566 Kanamaru Aug 2005 A1
20050173135 Almen Aug 2005 A1
20050192627 Whisenant et al. Sep 2005 A1
20050216030 Sepetka et al. Sep 2005 A1
20050216050 Sepetka et al. Sep 2005 A1
20050228417 Teitelbaum et al. Oct 2005 A1
20050251206 Maahs et al. Nov 2005 A1
20050251209 Saadat et al. Nov 2005 A1
20050267491 Kellett et al. Dec 2005 A1
20050273135 Chanduszko et al. Dec 2005 A1
20050288686 Sepetka et al. Dec 2005 A1
20060008332 Greenberg et al. Jan 2006 A1
20060009798 Callister et al. Jan 2006 A1
20060009799 Kleshinski et al. Jan 2006 A1
20060020286 Niermann Jan 2006 A1
20060030877 Martinez et al. Feb 2006 A1
20060041228 Vo et al. Feb 2006 A1
20060058836 Bose et al. Mar 2006 A1
20060058837 Bose et al. Mar 2006 A1
20060058838 Bose et al. Mar 2006 A1
20060064151 Guterman et al. Mar 2006 A1
20060069424 Acosta et al. Mar 2006 A1
20060074477 Berthiaume et al. Apr 2006 A1
20060149313 Arguello et al. Jul 2006 A1
20060155305 Freudenthal et al. Jul 2006 A1
20060161187 Levine et al. Jul 2006 A1
20060195137 Sepetka et al. Aug 2006 A1
20060224177 Finitsis Oct 2006 A1
20060224179 Kucharczyk et al. Oct 2006 A1
20060229638 Abrams et al. Oct 2006 A1
20060235501 Igaki Oct 2006 A1
20060241677 Johnson et al. Oct 2006 A1
20060282111 Morsi Dec 2006 A1
20060287668 Fawzi et al. Dec 2006 A1
20060287701 Pal Dec 2006 A1
20060293706 Shimon Dec 2006 A1
20070010857 Sugimoto et al. Jan 2007 A1
20070032879 Levine et al. Feb 2007 A1
20070088382 Bei et al. Apr 2007 A1
20070088383 Pal et al. Apr 2007 A1
20070118173 Magnuson et al. May 2007 A1
20070149997 Muller Jun 2007 A1
20070156170 Hancock et al. Jul 2007 A1
20070165170 Fukuda Jul 2007 A1
20070179527 Eskuri et al. Aug 2007 A1
20070191866 Palmer et al. Aug 2007 A1
20070198028 Miloslayski et al. Aug 2007 A1
20070198051 Clubb et al. Aug 2007 A1
20070198075 Levy Aug 2007 A1
20070208367 Fiorella et al. Sep 2007 A1
20070208371 French et al. Sep 2007 A1
20070225749 Martin et al. Sep 2007 A1
20070233175 Zaver et al. Oct 2007 A1
20070244505 Gilson et al. Oct 2007 A1
20070270902 Slazas et al. Nov 2007 A1
20070288054 Tanaka et al. Dec 2007 A1
20080045881 Teitelbaum et al. Feb 2008 A1
20080077227 Ouellette et al. Mar 2008 A1
20080082107 Miller et al. Apr 2008 A1
20080086190 Ta Apr 2008 A1
20080091223 Pokorney et al. Apr 2008 A1
20080097386 Osypka Apr 2008 A1
20080109031 Sepetka et al. May 2008 A1
20080109032 Sepetka et al. May 2008 A1
20080119886 Greenhalgh et al. May 2008 A1
20080177296 Sepetka et al. Jul 2008 A1
20080178890 Townsend et al. Jul 2008 A1
20080183197 Sepetka et al. Jul 2008 A1
20080183198 Sepetka et al. Jul 2008 A1
20080183205 Sepetka et al. Jul 2008 A1
20080188876 Sepetka et al. Aug 2008 A1
20080188885 Sepetka et al. Aug 2008 A1
20080188887 Batiste Aug 2008 A1
20080200946 Braun et al. Aug 2008 A1
20080200947 Kusleika et al. Aug 2008 A1
20080215077 Sepetka et al. Sep 2008 A1
20080221600 Dieck et al. Sep 2008 A1
20080228209 DeMello et al. Sep 2008 A1
20080234706 Sepetka et al. Sep 2008 A1
20080243170 Jenson et al. Oct 2008 A1
20080255596 Jenson et al. Oct 2008 A1
20080262528 Martin Oct 2008 A1
20080262532 Martin Oct 2008 A1
20080269871 Eli Oct 2008 A1
20080275488 Fleming Nov 2008 A1
20080275493 Farmiga Nov 2008 A1
20080281350 Sepetka et al. Nov 2008 A1
20080312681 Ansel et al. Dec 2008 A1
20090005858 Young et al. Jan 2009 A1
20090024157 Anukhin Jan 2009 A1
20090030443 Buser et al. Jan 2009 A1
20090062841 Amplatz et al. Mar 2009 A1
20090069828 Martin et al. Mar 2009 A1
20090076539 Valaie Mar 2009 A1
20090088793 Bagaoisan et al. Apr 2009 A1
20090088795 Cahill Apr 2009 A1
20090105722 Fulkerson et al. Apr 2009 A1
20090105737 Fulkerson et al. Apr 2009 A1
20090105747 Chanduszko et al. Apr 2009 A1
20090149881 Vale et al. Jun 2009 A1
20090163851 Holloway et al. Jun 2009 A1
20090177206 Lozier et al. Jul 2009 A1
20090182336 Brenzel et al. Jul 2009 A1
20090281610 Parker Nov 2009 A1
20090281619 Le et al. Nov 2009 A1
20090292297 Ferrere Nov 2009 A1
20090292307 Razack Nov 2009 A1
20090299393 Martin et al. Dec 2009 A1
20090299403 Chanduszko et al. Dec 2009 A1
20090306702 Miloslayski et al. Dec 2009 A1
20090326636 Hashimoto et al. Dec 2009 A1
20100004607 Wilson et al. Jan 2010 A1
20100076482 Shu et al. Mar 2010 A1
20100087850 Razack Apr 2010 A1
20100087908 Hilaire et al. Apr 2010 A1
20100114017 Lenker et al. May 2010 A1
20100125326 Kalstad et al. May 2010 A1
20100125327 Agnew May 2010 A1
20100191272 Keating Jul 2010 A1
20100211094 Sargent, Jr. Aug 2010 A1
20100268264 Bonnette et al. Oct 2010 A1
20100268265 Krolik et al. Oct 2010 A1
20100274277 Eaton Oct 2010 A1
20100318178 Rapaport et al. Dec 2010 A1
20100324649 Mattsson et al. Dec 2010 A1
20100331949 Habib Dec 2010 A1
20110009875 Grandfield et al. Jan 2011 A1
20110009940 Grandfield et al. Jan 2011 A1
20110022149 Cox et al. Jan 2011 A1
20110054504 Porter Mar 2011 A1
20110054514 Arcand et al. Mar 2011 A1
20110054516 Keegan et al. Mar 2011 A1
20110060212 Slee et al. Mar 2011 A1
20110060359 Hannes et al. Mar 2011 A1
20110106137 Shimon May 2011 A1
20110125181 Brady et al. May 2011 A1
20110152920 Eckhouse et al. Jun 2011 A1
20110160763 Ferrera et al. Jun 2011 A1
20110166586 Sepetka et al. Jul 2011 A1
20110196414 Porter et al. Aug 2011 A1
20110202088 Eckhouse et al. Aug 2011 A1
20110208233 McGuckin, Jr. et al. Aug 2011 A1
20110213297 Aklog et al. Sep 2011 A1
20110213393 Aklog et al. Sep 2011 A1
20110213403 Aboytes Sep 2011 A1
20110224707 Miloslayski et al. Sep 2011 A1
20110276120 Gilson et al. Nov 2011 A1
20120041449 Eckhouse et al. Feb 2012 A1
20120041474 Eckhouse et al. Feb 2012 A1
20120059356 di Palma et al. Mar 2012 A1
20120083823 Shrivastava et al. Apr 2012 A1
20120083868 Shrivastava et al. Apr 2012 A1
20120089216 Rapaport et al. Apr 2012 A1
20120101510 Lenker et al. Apr 2012 A1
20120123466 Porter et al. May 2012 A1
20120143237 Cam et al. Jun 2012 A1
20120150147 Leynov et al. Jun 2012 A1
20120165858 Eckhouse et al. Jun 2012 A1
20120165859 Eckhouse et al. Jun 2012 A1
20120209312 Aggerholm et al. Aug 2012 A1
20120215250 Grandfield et al. Aug 2012 A1
20120277788 Cattaneo Nov 2012 A1
20120283768 Cox et al. Nov 2012 A1
20120296362 Cam et al. Nov 2012 A1
20120316600 Ferrera et al. Dec 2012 A1
20120330350 Jones et al. Dec 2012 A1
20130030460 Marks et al. Jan 2013 A1
20130030461 Marks et al. Jan 2013 A1
20130046330 McIntosh et al. Feb 2013 A1
20130046333 Jones et al. Feb 2013 A1
20130046334 Jones et al. Feb 2013 A1
20130116774 Strauss et al. May 2013 A1
20130131614 Hassan et al. May 2013 A1
20130144311 Fung et al. Jun 2013 A1
20130144326 Brady et al. Jun 2013 A1
20130158592 Porter Jun 2013 A1
20130184739 Brady et al. Jul 2013 A1
20130197567 Brady et al. Aug 2013 A1
20130226146 Tekulve Aug 2013 A1
20130268050 Wilson et al. Oct 2013 A1
20130271788 Utsunomiya Oct 2013 A1
20130277079 Tsuzuki et al. Oct 2013 A1
20130281788 Garrison Oct 2013 A1
20130325051 Martin et al. Dec 2013 A1
20130325055 Eckhouse et al. Dec 2013 A1
20130325056 Eckhouse et al. Dec 2013 A1
20130345739 Brady et al. Dec 2013 A1
20140046359 Bowman et al. Feb 2014 A1
20140121672 Folk May 2014 A1
20140128905 Molaei May 2014 A1
20140135812 Divino et al. May 2014 A1
20140180377 Bose et al. Jun 2014 A1
20140180397 Gerberding et al. Jun 2014 A1
20140183077 Rosendall et al. Jul 2014 A1
20140194911 Johnson et al. Jul 2014 A1
20140194919 Losordo et al. Jul 2014 A1
20140200607 Sepetka et al. Jul 2014 A1
20140200608 Brady Jul 2014 A1
20140236220 Inoue Aug 2014 A1
20140257362 Eidenschink Sep 2014 A1
20140276922 McLain et al. Sep 2014 A1
20140277079 Vale et al. Sep 2014 A1
20140303667 Cox Oct 2014 A1
20140309657 Ben-Ami Oct 2014 A1
20140309673 Dacuycuy et al. Oct 2014 A1
20140330302 Tekulve et al. Nov 2014 A1
20140343585 Ferrera et al. Nov 2014 A1
20140371769 Vale et al. Dec 2014 A1
20140371779 Vale Dec 2014 A1
20140371780 Vale et al. Dec 2014 A1
20140372779 Wong et al. Dec 2014 A1
20140379023 Brady et al. Dec 2014 A1
20150018859 Quick et al. Jan 2015 A1
20150018860 Quick et al. Jan 2015 A1
20150032144 Holloway Jan 2015 A1
20150080937 Davidson Mar 2015 A1
20150112376 Molaei et al. Apr 2015 A1
20150133990 Davidson May 2015 A1
20150150672 Ma Jun 2015 A1
20150164523 Brady et al. Jun 2015 A1
20150250497 Marks et al. Sep 2015 A1
20150257775 Gilvarry et al. Sep 2015 A1
20150272716 Pinchuk Oct 2015 A1
20150297252 Miloslavski et al. Oct 2015 A1
20150313617 Grandfield et al. Nov 2015 A1
20150320431 Ulm Nov 2015 A1
20150352325 Quick Dec 2015 A1
20150359547 Vale et al. Dec 2015 A1
20150366650 Zi Dec 2015 A1
20150374391 Quick et al. Dec 2015 A1
20150374393 Brady et al. Dec 2015 A1
20150374479 Vale Dec 2015 A1
20160015402 Brady et al. Jan 2016 A1
20160022269 Ganske et al. Jan 2016 A1
20160022296 Brady et al. Jan 2016 A1
20160045298 Thinnes, Jr. et al. Feb 2016 A1
20160066921 Seifert et al. Mar 2016 A1
20160106448 Brady et al. Apr 2016 A1
20160106449 Brady et al. Apr 2016 A1
20160113663 Brady et al. Apr 2016 A1
20160113664 Brady et al. Apr 2016 A1
20160113665 Brady et al. Apr 2016 A1
20160120558 Brady et al. May 2016 A1
20160143653 Vale et al. May 2016 A1
20160192953 Brady et al. Jul 2016 A1
20160192954 Brady et al. Jul 2016 A1
20160192955 Brady et al. Jul 2016 A1
20160192956 Brady et al. Jul 2016 A1
20160256180 Vale et al. Sep 2016 A1
20160303381 Pierce Oct 2016 A1
20160317168 Brady et al. Nov 2016 A1
20170007264 Cruise et al. Jan 2017 A1
20170007265 Guo et al. Jan 2017 A1
20170020542 Martin Jan 2017 A1
20170020670 Murray et al. Jan 2017 A1
20170020700 Bienvenu et al. Jan 2017 A1
20170027640 Kunis et al. Feb 2017 A1
20170027692 Bonhoeffer et al. Feb 2017 A1
20170027725 Argentine Feb 2017 A1
20170035436 Morita Feb 2017 A1
20170035567 Duffy Feb 2017 A1
20170042548 Lam Feb 2017 A1
20170049596 Schabert Feb 2017 A1
20170071614 Vale et al. Mar 2017 A1
20170071737 Kelley Mar 2017 A1
20170072452 Monetti et al. Mar 2017 A1
20170079671 Morero et al. Mar 2017 A1
20170079680 Bowman Mar 2017 A1
20170079766 Wang et al. Mar 2017 A1
20170079767 Leon-Yip Mar 2017 A1
20170079812 Lam et al. Mar 2017 A1
20170079817 Sepetka et al. Mar 2017 A1
20170079819 Pung et al. Mar 2017 A1
20170079820 Lam et al. Mar 2017 A1
20170086851 Wallace et al. Mar 2017 A1
20170086862 Vale et al. Mar 2017 A1
20170086863 Brady et al. Mar 2017 A1
20170086996 Peterson et al. Mar 2017 A1
20170095259 Tompkins et al. Apr 2017 A1
20170100126 Bowman et al. Apr 2017 A1
20170100141 Morero et al. Apr 2017 A1
20170100143 Grandfield Apr 2017 A1
20170100183 Iaizzo et al. Apr 2017 A1
20170105743 Vale et al. Apr 2017 A1
20170112515 Brady et al. Apr 2017 A1
20170112647 Sachar et al. Apr 2017 A1
20170113023 Steingisser et al. Apr 2017 A1
20170119409 Ma May 2017 A1
20170147765 Mehta May 2017 A1
20170150979 Ulm Jun 2017 A1
20170151032 Loisel Jun 2017 A1
20170165062 Rothstein Jun 2017 A1
20170165065 Rothstein et al. Jun 2017 A1
20170165454 Tuohy et al. Jun 2017 A1
20170172581 Bose et al. Jun 2017 A1
20170172766 Vong et al. Jun 2017 A1
20170172772 Khenansho Jun 2017 A1
20170189033 Sepetka et al. Jul 2017 A1
20170189035 Porter Jul 2017 A1
20170215902 Leynov et al. Aug 2017 A1
20170216484 Cruise et al. Aug 2017 A1
20170224350 Shimizu et al. Aug 2017 A1
20170224355 Bowman et al. Aug 2017 A1
20170224467 Piccagli et al. Aug 2017 A1
20170224511 Dwork et al. Aug 2017 A1
20170224953 Tran et al. Aug 2017 A1
20170231749 Perkins et al. Aug 2017 A1
20170252064 Staunton Sep 2017 A1
20170265983 Lam et al. Sep 2017 A1
20170281192 Tieu et al. Oct 2017 A1
20170281331 Perkins et al. Oct 2017 A1
20170281344 Costello Oct 2017 A1
20170281909 Northrop et al. Oct 2017 A1
20170281912 Melder et al. Oct 2017 A1
20170290593 Cruise et al. Oct 2017 A1
20170290654 Sethna Oct 2017 A1
20170296324 Argentine Oct 2017 A1
20170296325 Marrocco et al. Oct 2017 A1
20170303939 Greenhalgh et al. Oct 2017 A1
20170303942 Greenhalgh et al. Oct 2017 A1
20170303947 Greenhalgh et al. Oct 2017 A1
20170303948 Wallace et al. Oct 2017 A1
20170304041 Argentine Oct 2017 A1
20170304097 Corwin et al. Oct 2017 A1
20170304595 Nagasrinivasa et al. Oct 2017 A1
20170312109 Le Nov 2017 A1
20170312484 Shipley et al. Nov 2017 A1
20170316561 Helm et al. Nov 2017 A1
20170319826 Bowman et al. Nov 2017 A1
20170333228 Orth et al. Nov 2017 A1
20170333236 Greenan Nov 2017 A1
20170333678 Bowman et al. Nov 2017 A1
20170340383 Bloom et al. Nov 2017 A1
20170348014 Wallace et al. Dec 2017 A1
20170348514 Guyon et al. Dec 2017 A1
20180263650 Iwanami et al. Sep 2018 A1
20190000492 Casey et al. Jan 2019 A1
20190167284 Friedman et al. Jun 2019 A1
20190374239 Martin et al. Dec 2019 A1
20190380723 Grandfield et al. Dec 2019 A1
20190388097 Girdhar et al. Dec 2019 A1
20200100804 Casey et al. Apr 2020 A1
Foreign Referenced Citations (95)
Number Date Country
2557083 Jun 2003 CN
101172051 May 2008 CN
102307613 Jan 2012 CN
102596098 Jul 2012 CN
104042304 Sep 2014 CN
105662532 Jun 2016 CN
205359559 Jul 2016 CN
107530090 Jan 2018 CN
202009001951 Apr 2010 DE
102009056450 Jun 2011 DE
102010010849 Sep 2011 DE
102010014778 Oct 2011 DE
102010024085 Dec 2011 DE
102011014586 Sep 2012 DE
2301450 Mar 2011 EP
2438891 Apr 2012 EP
2628455 Aug 2013 EP
3156004 Apr 2017 EP
2427554 Jan 2007 GB
2494820 Mar 2013 GB
H0919438 Jan 1997 JP
2014511223 May 2014 JP
2014525796 Oct 2014 JP
2019-526365 Sep 2019 JP
9424926 Nov 1994 WO
9727808 Aug 1997 WO
9738631 Oct 1997 WO
9920335 Apr 1999 WO
9956801 Nov 1999 WO
9960933 Dec 1999 WO
0121077 Mar 2001 WO
0202162 Jan 2002 WO
0211627 Feb 2002 WO
0243616 Jun 2002 WO
02070061 Sep 2002 WO
02094111 Nov 2002 WO
03002006 Jan 2003 WO
03030751 Apr 2003 WO
03051448 Jun 2003 WO
2004028571 Apr 2004 WO
2004056275 Jul 2004 WO
2005000130 Jan 2005 WO
2005027779 Mar 2005 WO
2006021407 Mar 2006 WO
2006031410 Mar 2006 WO
2006107641 Oct 2006 WO
2006135823 Dec 2006 WO
2007054307 May 2007 WO
2007068424 Jun 2007 WO
2008034615 Mar 2008 WO
2008051431 May 2008 WO
2008131116 Oct 2008 WO
2008135823 Nov 2008 WO
2009031338 Mar 2009 WO
2009076482 Jun 2009 WO
2009086482 Jul 2009 WO
2009105710 Aug 2009 WO
2010010545 Jan 2010 WO
2010046897 Apr 2010 WO
2010075565 Jul 2010 WO
2010102307 Sep 2010 WO
2010146581 Dec 2010 WO
2011013556 Feb 2011 WO
2011066961 Jun 2011 WO
2011082319 Jul 2011 WO
2011095352 Aug 2011 WO
2011106426 Sep 2011 WO
2011110316 Sep 2011 WO
2011135556 Nov 2011 WO
2012052982 Apr 2012 WO
2012064726 May 2012 WO
2012081020 Jun 2012 WO
2012110619 Aug 2012 WO
2012120490 Sep 2012 WO
WO-2012120490 Sep 2012 WO
2012156924 Nov 2012 WO
2013016435 Jan 2013 WO
2013072777 May 2013 WO
2013105099 Jul 2013 WO
2013109756 Jul 2013 WO
2013187927 Dec 2013 WO
2014047650 Mar 2014 WO
2014081892 May 2014 WO
2014139845 Sep 2014 WO
2014169266 Oct 2014 WO
2014178198 Nov 2014 WO
2015061365 Apr 2015 WO
2015103547 Jul 2015 WO
2015134625 Sep 2015 WO
2015179324 Nov 2015 WO
2015189354 Dec 2015 WO
2016010995 Jan 2016 WO
2016089451 Jun 2016 WO
2017089424 Jan 2017 WO
2017089424 Jun 2017 WO
Non-Patent Literature Citations (6)
Entry
US 6,348,062 B1, 02/2002, Hopkins et al. (withdrawn)
Communication pursuant to Article 94(3) EPC issued in corresponding European Patent Application No. 17 764 364.0 dated Mar. 9, 2020.
International Search Report and Written Opinion issued for corresponding International Application No. PCT/EP2017/072030 dated Apr. 9, 2018.
Chinese Search Report issued in corresponding Chinese Patent Application No. 201780068422.4 dated Dec. 30, 2020. Filed with English Translation.
Search Report issued in corresponding Chinese Patent Application No. 201680080064.4 dated Jun. 9, 2020 (English translation only).
Notification of Reasons for Refusal issued in corresponding Japanese Design Patent Application No. 2020-027634 dated Jun. 1, 2021, English translation only.
Related Publications (1)
Number Date Country
20200305900 A1 Oct 2020 US
Provisional Applications (1)
Number Date Country
62383905 Sep 2016 US